Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,19927376,nK(A),"The affinity of HSA and AGP to (+)-THP, expressed as nK(A), were 9.0 x 10(3) M(-1) and 2.34 x 10(5) M(-1), respectively, which were notablely higher than to (-)-THP, with the nK(A) of 3.4 x 10(3) M(-1) and 1.44 x 10(5) M(-1), respectively.","Stereoselective protein binding of tetrahydropalmatine enantiomers in human plasma, HSA, and AGP, but not in rat plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19927376/),1/[M],9.0 x 10(3),308,DB00458,Imipramine
,19927376,nK(A),"The affinity of HSA and AGP to (+)-THP, expressed as nK(A), were 9.0 x 10(3) M(-1) and 2.34 x 10(5) M(-1), respectively, which were notablely higher than to (-)-THP, with the nK(A) of 3.4 x 10(3) M(-1) and 1.44 x 10(5) M(-1), respectively.","Stereoselective protein binding of tetrahydropalmatine enantiomers in human plasma, HSA, and AGP, but not in rat plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19927376/),1/[M],2.34 x 10(5),309,DB00458,Imipramine
,19927376,nK(A),"The affinity of HSA and AGP to (+)-THP, expressed as nK(A), were 9.0 x 10(3) M(-1) and 2.34 x 10(5) M(-1), respectively, which were notablely higher than to (-)-THP, with the nK(A) of 3.4 x 10(3) M(-1) and 1.44 x 10(5) M(-1), respectively.","Stereoselective protein binding of tetrahydropalmatine enantiomers in human plasma, HSA, and AGP, but not in rat plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19927376/),1/[M],3.4 x 10(3),310,DB00458,Imipramine
,19927376,nK(A),"The affinity of HSA and AGP to (+)-THP, expressed as nK(A), were 9.0 x 10(3) M(-1) and 2.34 x 10(5) M(-1), respectively, which were notablely higher than to (-)-THP, with the nK(A) of 3.4 x 10(3) M(-1) and 1.44 x 10(5) M(-1), respectively.","Stereoselective protein binding of tetrahydropalmatine enantiomers in human plasma, HSA, and AGP, but not in rat plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19927376/),1/[M],1.44 x 10(5),311,DB00458,Imipramine
,7550984,detection limit,The assay allowed the simultaneous determination of all analytes in 1 ml of urine and the detection limit was 2 ng/ml with a signal-to-noise ratio of 3.,Development and preliminary application of high-performance liquid chromatographic assay of urinary metabolites of diazepam in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7550984/),[ng] / [ml],2,6147,DB00458,Imipramine
,7550984,signal-to-noise ratio,The assay allowed the simultaneous determination of all analytes in 1 ml of urine and the detection limit was 2 ng/ml with a signal-to-noise ratio of 3.,Development and preliminary application of high-performance liquid chromatographic assay of urinary metabolites of diazepam in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7550984/),,3,6148,DB00458,Imipramine
>,7550984,Recoveries,Recoveries of the analytes and the internal standard (prazepam) were > 82%.,Development and preliminary application of high-performance liquid chromatographic assay of urinary metabolites of diazepam in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7550984/),%,82,6149,DB00458,Imipramine
,7550984,cumulative urinary excretions,"The mean (+/- S.D.) cumulative urinary excretions of DMDZP, TZP and OZP over 96 h after a single oral administration of DZP were 3.9 +/- 0.4, 6.6 +/- 1.4 and 2.8 +/- 0.6% of the dose, respectively.",Development and preliminary application of high-performance liquid chromatographic assay of urinary metabolites of diazepam in humans. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7550984/),%,3.9,6150,DB00458,Imipramine
,7550984,cumulative urinary excretions,"The mean (+/- S.D.) cumulative urinary excretions of DMDZP, TZP and OZP over 96 h after a single oral administration of DZP were 3.9 +/- 0.4, 6.6 +/- 1.4 and 2.8 +/- 0.6% of the dose, respectively.",Development and preliminary application of high-performance liquid chromatographic assay of urinary metabolites of diazepam in humans. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7550984/),%,6.6,6151,DB00458,Imipramine
,7550984,cumulative urinary excretions,"The mean (+/- S.D.) cumulative urinary excretions of DMDZP, TZP and OZP over 96 h after a single oral administration of DZP were 3.9 +/- 0.4, 6.6 +/- 1.4 and 2.8 +/- 0.6% of the dose, respectively.",Development and preliminary application of high-performance liquid chromatographic assay of urinary metabolites of diazepam in humans. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7550984/),%,2.8,6152,DB00458,Imipramine
less,1815435,clearance,Two slow metabolizers were identified (clearance less than 0.10 L/kg/h).,Early individualization of tricyclic antidepressant dosing using a Bayesian pharmacokinetic model. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1815435/),[l] / [hÂ·kg],0.10,8081,DB00458,Imipramine
,3067542,clearance,Imipramine has a high clearance (0.8-1.5 l/min) and a corresponding high first pass elimination (30-70%).,Imipramine: a model substance in pharmacokinetic research. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3067542/),[l] / [min],0.8-1.5,18111,DB00458,Imipramine
,3067542,Volume of distribution,Volume of distribution is high (650-1100 1) and half-lives accordingly of medium length (6-12 h).,Imipramine: a model substance in pharmacokinetic research. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3067542/),1,650-1100,18112,DB00458,Imipramine
,3067542,half-lives,Volume of distribution is high (650-1100 1) and half-lives accordingly of medium length (6-12 h).,Imipramine: a model substance in pharmacokinetic research. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3067542/),h,6-12,18113,DB00458,Imipramine
,6427820,t1/2,"The t1/2 of IMI and 2-hydroxyimipramine (2-OH-IMI) was 6-18 h, while that of DMI and 2- hydroxydesipramine (2-OH-DMI) was 12-36 h.",The analysis and disposition of imipramine and its active metabolites in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6427820/),h,6-18,20056,DB00458,Imipramine
,6427820,t1/2,"The t1/2 of IMI and 2-hydroxyimipramine (2-OH-IMI) was 6-18 h, while that of DMI and 2- hydroxydesipramine (2-OH-DMI) was 12-36 h.",The analysis and disposition of imipramine and its active metabolites in man. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6427820/),h,12-36,20057,DB00458,Imipramine
less,2197816,oral bioavailability,Significant first-pass metabolism reduces oral bioavailability to less than 62 percent.,Clomipramine: a tricyclic antidepressant effective in obsessive compulsive disorder. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2197816/),%,62,22476,DB00458,Imipramine
,2197816,volume of distribution,The drug is widely distributed throughout the body (volume of distribution 9-25 L/kg) and is 90-98 percent protein-bound.,Clomipramine: a tricyclic antidepressant effective in obsessive compulsive disorder. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2197816/),[l] / [kg],9-25,22477,DB00458,Imipramine
,2197816,plasma half-life,"Clomipramine follows first-order elimination pharmacokinetics, with a plasma half-life of 20-24 hours.",Clomipramine: a tricyclic antidepressant effective in obsessive compulsive disorder. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2197816/),h,20-24,22478,DB00458,Imipramine
below,9210442,detection limit,"The detection limit is below 5 ng/ml for both compounds, and extraction recoveries close to 80%.",Simultaneous determination of verapamil and norverapamil in biological samples by high-performance liquid chromatography using ultraviolet detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9210442/),[ng] / [ml],5,27566,DB00458,Imipramine
,9210442,extraction recoveries,"The detection limit is below 5 ng/ml for both compounds, and extraction recoveries close to 80%.",Simultaneous determination of verapamil and norverapamil in biological samples by high-performance liquid chromatography using ultraviolet detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9210442/),%,80,27567,DB00458,Imipramine
,8236366,retention times,"Under these conditions, no interference in the assay was observed, and the retention times of NFLU, DOX, FLU, AMI, IMI, NTRIP, and DES were 7.8, 11.6, 16, 17.8, 20.9, 31, and 35 min, respectively.","Concurrent liquid chromatographic measurement of fluoxetine, amitriptyline, imipramine, and their active metabolites norfluoxetine, nortriptyline, and desipramine in plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8236366/),min,7.8,30263,DB00458,Imipramine
,8236366,retention times,"Under these conditions, no interference in the assay was observed, and the retention times of NFLU, DOX, FLU, AMI, IMI, NTRIP, and DES were 7.8, 11.6, 16, 17.8, 20.9, 31, and 35 min, respectively.","Concurrent liquid chromatographic measurement of fluoxetine, amitriptyline, imipramine, and their active metabolites norfluoxetine, nortriptyline, and desipramine in plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8236366/),min,11.6,30264,DB00458,Imipramine
,8236366,retention times,"Under these conditions, no interference in the assay was observed, and the retention times of NFLU, DOX, FLU, AMI, IMI, NTRIP, and DES were 7.8, 11.6, 16, 17.8, 20.9, 31, and 35 min, respectively.","Concurrent liquid chromatographic measurement of fluoxetine, amitriptyline, imipramine, and their active metabolites norfluoxetine, nortriptyline, and desipramine in plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8236366/),min,16,30265,DB00458,Imipramine
,8236366,retention times,"Under these conditions, no interference in the assay was observed, and the retention times of NFLU, DOX, FLU, AMI, IMI, NTRIP, and DES were 7.8, 11.6, 16, 17.8, 20.9, 31, and 35 min, respectively.","Concurrent liquid chromatographic measurement of fluoxetine, amitriptyline, imipramine, and their active metabolites norfluoxetine, nortriptyline, and desipramine in plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8236366/),min,17.8,30266,DB00458,Imipramine
,8236366,retention times,"Under these conditions, no interference in the assay was observed, and the retention times of NFLU, DOX, FLU, AMI, IMI, NTRIP, and DES were 7.8, 11.6, 16, 17.8, 20.9, 31, and 35 min, respectively.","Concurrent liquid chromatographic measurement of fluoxetine, amitriptyline, imipramine, and their active metabolites norfluoxetine, nortriptyline, and desipramine in plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8236366/),min,20.9,30267,DB00458,Imipramine
,8236366,retention times,"Under these conditions, no interference in the assay was observed, and the retention times of NFLU, DOX, FLU, AMI, IMI, NTRIP, and DES were 7.8, 11.6, 16, 17.8, 20.9, 31, and 35 min, respectively.","Concurrent liquid chromatographic measurement of fluoxetine, amitriptyline, imipramine, and their active metabolites norfluoxetine, nortriptyline, and desipramine in plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8236366/),min,31,30268,DB00458,Imipramine
,8236366,retention times,"Under these conditions, no interference in the assay was observed, and the retention times of NFLU, DOX, FLU, AMI, IMI, NTRIP, and DES were 7.8, 11.6, 16, 17.8, 20.9, 31, and 35 min, respectively.","Concurrent liquid chromatographic measurement of fluoxetine, amitriptyline, imipramine, and their active metabolites norfluoxetine, nortriptyline, and desipramine in plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8236366/),min,35,30269,DB00458,Imipramine
,8786570,Vd,"In transgenic mice, there were significant decreases in the serum unbound fraction (0.62+/- 0.38 vs.2.48 +/- 0.43%), Vd (9.0 +/- 2.5 vs. 22.4 +/- 3.2 liters/kg), T1/2 (35.0 +/- 7.6 vs. 65.3 +/- 7.6 min) and fraction of dose excreted unchanged in urine (0.14 +/- 0.07 vs. 0.70 +/- 0.20%) with no significant alterations in systemic clearance (204.7 +/- 56.1 vs. 292.8 +/- 58.4 ml/min/kg) compared to control values.",Altered disposition and antidepressant activity of imipramine in transgenic mice with elevated alpha-1-acid glycoprotein. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8786570/),[l] / [kg],9.0,33342,DB00458,Imipramine
,8786570,Vd,"In transgenic mice, there were significant decreases in the serum unbound fraction (0.62+/- 0.38 vs.2.48 +/- 0.43%), Vd (9.0 +/- 2.5 vs. 22.4 +/- 3.2 liters/kg), T1/2 (35.0 +/- 7.6 vs. 65.3 +/- 7.6 min) and fraction of dose excreted unchanged in urine (0.14 +/- 0.07 vs. 0.70 +/- 0.20%) with no significant alterations in systemic clearance (204.7 +/- 56.1 vs. 292.8 +/- 58.4 ml/min/kg) compared to control values.",Altered disposition and antidepressant activity of imipramine in transgenic mice with elevated alpha-1-acid glycoprotein. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8786570/),[l] / [kg],22.4,33343,DB00458,Imipramine
,8786570,T1/2,"In transgenic mice, there were significant decreases in the serum unbound fraction (0.62+/- 0.38 vs.2.48 +/- 0.43%), Vd (9.0 +/- 2.5 vs. 22.4 +/- 3.2 liters/kg), T1/2 (35.0 +/- 7.6 vs. 65.3 +/- 7.6 min) and fraction of dose excreted unchanged in urine (0.14 +/- 0.07 vs. 0.70 +/- 0.20%) with no significant alterations in systemic clearance (204.7 +/- 56.1 vs. 292.8 +/- 58.4 ml/min/kg) compared to control values.",Altered disposition and antidepressant activity of imipramine in transgenic mice with elevated alpha-1-acid glycoprotein. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8786570/),min,35.0,33344,DB00458,Imipramine
,8786570,T1/2,"In transgenic mice, there were significant decreases in the serum unbound fraction (0.62+/- 0.38 vs.2.48 +/- 0.43%), Vd (9.0 +/- 2.5 vs. 22.4 +/- 3.2 liters/kg), T1/2 (35.0 +/- 7.6 vs. 65.3 +/- 7.6 min) and fraction of dose excreted unchanged in urine (0.14 +/- 0.07 vs. 0.70 +/- 0.20%) with no significant alterations in systemic clearance (204.7 +/- 56.1 vs. 292.8 +/- 58.4 ml/min/kg) compared to control values.",Altered disposition and antidepressant activity of imipramine in transgenic mice with elevated alpha-1-acid glycoprotein. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8786570/),min,65.3,33345,DB00458,Imipramine
,8786570,fraction of dose excreted unchanged in,"In transgenic mice, there were significant decreases in the serum unbound fraction (0.62+/- 0.38 vs.2.48 +/- 0.43%), Vd (9.0 +/- 2.5 vs. 22.4 +/- 3.2 liters/kg), T1/2 (35.0 +/- 7.6 vs. 65.3 +/- 7.6 min) and fraction of dose excreted unchanged in urine (0.14 +/- 0.07 vs. 0.70 +/- 0.20%) with no significant alterations in systemic clearance (204.7 +/- 56.1 vs. 292.8 +/- 58.4 ml/min/kg) compared to control values.",Altered disposition and antidepressant activity of imipramine in transgenic mice with elevated alpha-1-acid glycoprotein. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8786570/),%,0.14,33346,DB00458,Imipramine
,8786570,fraction of dose excreted unchanged in,"In transgenic mice, there were significant decreases in the serum unbound fraction (0.62+/- 0.38 vs.2.48 +/- 0.43%), Vd (9.0 +/- 2.5 vs. 22.4 +/- 3.2 liters/kg), T1/2 (35.0 +/- 7.6 vs. 65.3 +/- 7.6 min) and fraction of dose excreted unchanged in urine (0.14 +/- 0.07 vs. 0.70 +/- 0.20%) with no significant alterations in systemic clearance (204.7 +/- 56.1 vs. 292.8 +/- 58.4 ml/min/kg) compared to control values.",Altered disposition and antidepressant activity of imipramine in transgenic mice with elevated alpha-1-acid glycoprotein. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8786570/),%,0.70,33347,DB00458,Imipramine
,8786570,systemic clearance,"In transgenic mice, there were significant decreases in the serum unbound fraction (0.62+/- 0.38 vs.2.48 +/- 0.43%), Vd (9.0 +/- 2.5 vs. 22.4 +/- 3.2 liters/kg), T1/2 (35.0 +/- 7.6 vs. 65.3 +/- 7.6 min) and fraction of dose excreted unchanged in urine (0.14 +/- 0.07 vs. 0.70 +/- 0.20%) with no significant alterations in systemic clearance (204.7 +/- 56.1 vs. 292.8 +/- 58.4 ml/min/kg) compared to control values.",Altered disposition and antidepressant activity of imipramine in transgenic mice with elevated alpha-1-acid glycoprotein. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8786570/),[ml] / [kgÂ·min],204.7,33348,DB00458,Imipramine
,8786570,systemic clearance,"In transgenic mice, there were significant decreases in the serum unbound fraction (0.62+/- 0.38 vs.2.48 +/- 0.43%), Vd (9.0 +/- 2.5 vs. 22.4 +/- 3.2 liters/kg), T1/2 (35.0 +/- 7.6 vs. 65.3 +/- 7.6 min) and fraction of dose excreted unchanged in urine (0.14 +/- 0.07 vs. 0.70 +/- 0.20%) with no significant alterations in systemic clearance (204.7 +/- 56.1 vs. 292.8 +/- 58.4 ml/min/kg) compared to control values.",Altered disposition and antidepressant activity of imipramine in transgenic mice with elevated alpha-1-acid glycoprotein. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8786570/),[ml] / [kgÂ·min],292.8,33349,DB00458,Imipramine
,11197075,Ki (inhibition constant),"Studies with control liver microsomes showed that amitriptyline and imipramine added to the incubation mixture in-vitro, competitively inhibited N-demethylation (Ki (inhibition constant) = 16 microM and 164 microM, respectively) and 5-sulphoxidation (Ki = 57 microM and 86 microM, respectively) of perazine, amitriptyline being a more potent inhibitor of perazine metabolism, especially with respect to N-demethylation.",Different effects of amitriptyline and imipramine on the pharmacokinetics and metabolism of perazine in rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11197075/),Î¼M,16,34677,DB00458,Imipramine
,11197075,Ki (inhibition constant),"Studies with control liver microsomes showed that amitriptyline and imipramine added to the incubation mixture in-vitro, competitively inhibited N-demethylation (Ki (inhibition constant) = 16 microM and 164 microM, respectively) and 5-sulphoxidation (Ki = 57 microM and 86 microM, respectively) of perazine, amitriptyline being a more potent inhibitor of perazine metabolism, especially with respect to N-demethylation.",Different effects of amitriptyline and imipramine on the pharmacokinetics and metabolism of perazine in rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11197075/),Î¼M,164,34678,DB00458,Imipramine
,11197075,Ki,"Studies with control liver microsomes showed that amitriptyline and imipramine added to the incubation mixture in-vitro, competitively inhibited N-demethylation (Ki (inhibition constant) = 16 microM and 164 microM, respectively) and 5-sulphoxidation (Ki = 57 microM and 86 microM, respectively) of perazine, amitriptyline being a more potent inhibitor of perazine metabolism, especially with respect to N-demethylation.",Different effects of amitriptyline and imipramine on the pharmacokinetics and metabolism of perazine in rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11197075/),Î¼M,57,34679,DB00458,Imipramine
,11197075,Ki,"Studies with control liver microsomes showed that amitriptyline and imipramine added to the incubation mixture in-vitro, competitively inhibited N-demethylation (Ki (inhibition constant) = 16 microM and 164 microM, respectively) and 5-sulphoxidation (Ki = 57 microM and 86 microM, respectively) of perazine, amitriptyline being a more potent inhibitor of perazine metabolism, especially with respect to N-demethylation.",Different effects of amitriptyline and imipramine on the pharmacokinetics and metabolism of perazine in rats. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11197075/),Î¼M,86,34680,DB00458,Imipramine
,2863107,mean residence time,The DMI concentration exceeded that of IMI in all tissues and DMI persisted in tissues longer: mean residence time for DMI in whole fetus was 21.2 hr compared to 3.5 hr for IMI.,Pharmacokinetics of imipramine and its major metabolites in pregnant rats and their fetuses following a single dose. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2863107/),h,21.2,35049,DB00458,Imipramine
,2863107,mean residence time,The DMI concentration exceeded that of IMI in all tissues and DMI persisted in tissues longer: mean residence time for DMI in whole fetus was 21.2 hr compared to 3.5 hr for IMI.,Pharmacokinetics of imipramine and its major metabolites in pregnant rats and their fetuses following a single dose. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2863107/),h,3.5,35050,DB00458,Imipramine
,6515713,retention times,"The retention times for IMI and viloxazine were 4.7 and 6.1 min, respectively.",A sensitive gas chromatographic assay for the determination of serum viloxazine concentration using a nitrogen-phosphorus-selective detector. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6515713/),min,4.7,35700,DB00458,Imipramine
,6515713,retention times,"The retention times for IMI and viloxazine were 4.7 and 6.1 min, respectively.",A sensitive gas chromatographic assay for the determination of serum viloxazine concentration using a nitrogen-phosphorus-selective detector. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6515713/),min,6.1,35701,DB00458,Imipramine
,6515713,recovery,The recovery averaged 64.5% and the lowest detection limit was 80 ng/ml.,A sensitive gas chromatographic assay for the determination of serum viloxazine concentration using a nitrogen-phosphorus-selective detector. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6515713/),%,64.5,35702,DB00458,Imipramine
,11360692,detection limit,The detection limit of plasma procaterol was 5 ng.L-1.,Determination of procaterol in human plasma by gas chromatography/electron impact ionization mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11360692/),[ng] / [l],5,38659,DB00458,Imipramine
,11360692,recovery,The average recovery of the assay was 99.1% +/- 1.3%.,Determination of procaterol in human plasma by gas chromatography/electron impact ionization mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11360692/),%,99.1,38660,DB00458,Imipramine
,20729023,m/z,"The ion transitions monitored were m/z 437.2 â 114.2 for KR-62980, m/z 281.3 â 86.1 for imipramine in multiple reaction monitoring (MRM) mode.","Determination of a peroxisome proliferator-activated receptor Î³ agonist, 1-(trans-methylimino-N-oxy)-6-(2-morpholinoethoxy-3-phenyl-1H-indene-2-carboxylic acid ethyl ester (KR-62980) in rat plasma by liquid chromatography-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20729023/),,437.2,39938,DB00458,Imipramine
,20729023,m/z,"The ion transitions monitored were m/z 437.2 â 114.2 for KR-62980, m/z 281.3 â 86.1 for imipramine in multiple reaction monitoring (MRM) mode.","Determination of a peroxisome proliferator-activated receptor Î³ agonist, 1-(trans-methylimino-N-oxy)-6-(2-morpholinoethoxy-3-phenyl-1H-indene-2-carboxylic acid ethyl ester (KR-62980) in rat plasma by liquid chromatography-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20729023/),,114.2,39939,DB00458,Imipramine
,20729023,m/z,"The ion transitions monitored were m/z 437.2 â 114.2 for KR-62980, m/z 281.3 â 86.1 for imipramine in multiple reaction monitoring (MRM) mode.","Determination of a peroxisome proliferator-activated receptor Î³ agonist, 1-(trans-methylimino-N-oxy)-6-(2-morpholinoethoxy-3-phenyl-1H-indene-2-carboxylic acid ethyl ester (KR-62980) in rat plasma by liquid chromatography-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20729023/),,281.3,39940,DB00458,Imipramine
,20729023,m/z,"The ion transitions monitored were m/z 437.2 â 114.2 for KR-62980, m/z 281.3 â 86.1 for imipramine in multiple reaction monitoring (MRM) mode.","Determination of a peroxisome proliferator-activated receptor Î³ agonist, 1-(trans-methylimino-N-oxy)-6-(2-morpholinoethoxy-3-phenyl-1H-indene-2-carboxylic acid ethyl ester (KR-62980) in rat plasma by liquid chromatography-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20729023/),,86.1,39941,DB00458,Imipramine
,20729023,percent recoveries,"The percent recoveries of KR-62980 and imipramine were 90.1 and 98.4% from rat plasma, respectively.","Determination of a peroxisome proliferator-activated receptor Î³ agonist, 1-(trans-methylimino-N-oxy)-6-(2-morpholinoethoxy-3-phenyl-1H-indene-2-carboxylic acid ethyl ester (KR-62980) in rat plasma by liquid chromatography-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20729023/),%,90.1,39942,DB00458,Imipramine
,20729023,percent recoveries,"The percent recoveries of KR-62980 and imipramine were 90.1 and 98.4% from rat plasma, respectively.","Determination of a peroxisome proliferator-activated receptor Î³ agonist, 1-(trans-methylimino-N-oxy)-6-(2-morpholinoethoxy-3-phenyl-1H-indene-2-carboxylic acid ethyl ester (KR-62980) in rat plasma by liquid chromatography-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20729023/),%,98.4,39943,DB00458,Imipramine
,9776341,Ka,"The antibodies used were a murine monoclonal IgG1 (Ka=3.8 10(7) M(-1)) at an IgG1/Imip molar ratio of 1000 (IgG1 1000), and a sheep polyclonal IgG (TAb, Ka=1.3 10(10) M(-1)) at IgG/ Imip molar ratios of 1, 10 and 100 (TAb1, TAb10 and TAb100).",Influence of various combinations of specific antibody dose and affinity on tissue imipramine redistribution. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9776341/),1/[M],3.8 10(7),41211,DB00458,Imipramine
,9776341,Ka,"The antibodies used were a murine monoclonal IgG1 (Ka=3.8 10(7) M(-1)) at an IgG1/Imip molar ratio of 1000 (IgG1 1000), and a sheep polyclonal IgG (TAb, Ka=1.3 10(10) M(-1)) at IgG/ Imip molar ratios of 1, 10 and 100 (TAb1, TAb10 and TAb100).",Influence of various combinations of specific antibody dose and affinity on tissue imipramine redistribution. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9776341/),1/[M],1.3 10(10),41212,DB00458,Imipramine
,9776341,NKa,Maximal plasma and tissue redistribution occurred when NKa=33.8 x 10(4).,Influence of various combinations of specific antibody dose and affinity on tissue imipramine redistribution. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9776341/),,33.8,41213,DB00458,Imipramine
,2641936,hepatic blood flow,to Miller at two different hepatic blood flow 6 and 11 ml/min respectively.,[Physiological principles of imipramine pharmacokinetics]. ,QH-Q55,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2641936/),[ml] / [min],6,42439,DB00458,Imipramine
,2641936,hepatic blood flow,to Miller at two different hepatic blood flow 6 and 11 ml/min respectively.,[Physiological principles of imipramine pharmacokinetics]. ,QH-Q55,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2641936/),[ml] / [min],11,42440,DB00458,Imipramine
,3604802,ED50,"The ED50 value for muricidal suppression was about 7.1 mg/kg (95% confidence limits, 5.4-9.3 mg/kg).",Effect of chlorpheniramine on muricide induced by thiamine deficiency: pharmacokinetic and behavioral studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3604802/),[mg] / [kg],7.1,50881,DB00458,Imipramine
,3604802,maximum effect,The maximum effect of muricidal suppression lasted for 1-2 hr after oral dosage (10 mg/kg).,Effect of chlorpheniramine on muricide induced by thiamine deficiency: pharmacokinetic and behavioral studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3604802/),h,1-2,50882,DB00458,Imipramine
,2293407,Mean residence time,"Mean residence time for DMI was significantly longer than for IMI (47.1 +/- 21.2 vs. 13.4 +/- 4.8 h, p less than 0.001).",Model for the kinetics of imipramine and its metabolites in adolescents. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2293407/),h,47.1,53167,DB00458,Imipramine
,2293407,Mean residence time,"Mean residence time for DMI was significantly longer than for IMI (47.1 +/- 21.2 vs. 13.4 +/- 4.8 h, p less than 0.001).",Model for the kinetics of imipramine and its metabolites in adolescents. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2293407/),h,13.4,53168,DB00458,Imipramine
,2293407,Clearance,"Clearance of DMI was considerably slower than that of IMI (0.67 +/- 0.45 vs. 2.18 +/- 1.33 l(kg.h), p less than 0.001).",Model for the kinetics of imipramine and its metabolites in adolescents. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2293407/),h)Â·l(kg,0.67,53169,DB00458,Imipramine
,2293407,Clearance,"Clearance of DMI was considerably slower than that of IMI (0.67 +/- 0.45 vs. 2.18 +/- 1.33 l(kg.h), p less than 0.001).",Model for the kinetics of imipramine and its metabolites in adolescents. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2293407/),h)Â·l(kg,2.18,53170,DB00458,Imipramine
,3133701,dose-normalized steady-state concentration,"The mean (SEM) values of the dose-normalized steady-state concentration and the apparent clearance after oral administration of this drug were 25.8 (4.8) ng.ml-1/mg.kg-1 and 2.529 (0.342) 1.h-1.kg-1, respectively.",Steady-state kinetics of doxepin and imipramine in Saudi patients with interethnic comparison. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3133701/),[ng] / [kgÂ·mgÂ·ml],25.8,53811,DB00458,Imipramine
,3133701,apparent clearance,"The mean (SEM) values of the dose-normalized steady-state concentration and the apparent clearance after oral administration of this drug were 25.8 (4.8) ng.ml-1/mg.kg-1 and 2.529 (0.342) 1.h-1.kg-1, respectively.",Steady-state kinetics of doxepin and imipramine in Saudi patients with interethnic comparison. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3133701/),[1] / [hÂ·kg],2.529,53812,DB00458,Imipramine
,3133701,dose-normalized steady-state concentration,"The mean dose-normalized steady-state concentration of IMI was 68.3 (19.7) ng.ml-1/mg.kg-1, and the mean apparent clearance after oral administration of IMI was 1.619 (0.353) 1.h-1. kg-1.",Steady-state kinetics of doxepin and imipramine in Saudi patients with interethnic comparison. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3133701/),[ng] / [kgÂ·mgÂ·ml],68.3,53813,DB00458,Imipramine
,3133701,apparent clearance,"The mean dose-normalized steady-state concentration of IMI was 68.3 (19.7) ng.ml-1/mg.kg-1, and the mean apparent clearance after oral administration of IMI was 1.619 (0.353) 1.h-1. kg-1.",Steady-state kinetics of doxepin and imipramine in Saudi patients with interethnic comparison. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3133701/),[1] / [hÂ·kg],1.619,53814,DB00458,Imipramine
,9278210,AUC,"Pretreatment with TAO significantly increased the AUC of IMI by 59% (1971 +/- 938 vs 3134 +/- 2000 microg l(-1) h, 95% confidence interval for difference between means: 218 to 2108 microg l(-1) h, P < 0.05) and decreased its oral clearance by 30% (60.9 +/- 27.4 vs 42.5 +/- 22.7 l h(-1), 95% confidence internal for difference between means: 7.2 to 31.7 l h(-1), P < 0.05).",Effect of troleandomycin on the pharmacokinetics of imipramine in Chinese: the role of CYP3A. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278210/),[hÂ·Î¼g] / [l],1971,54612,DB00458,Imipramine
,9278210,AUC,"Pretreatment with TAO significantly increased the AUC of IMI by 59% (1971 +/- 938 vs 3134 +/- 2000 microg l(-1) h, 95% confidence interval for difference between means: 218 to 2108 microg l(-1) h, P < 0.05) and decreased its oral clearance by 30% (60.9 +/- 27.4 vs 42.5 +/- 22.7 l h(-1), 95% confidence internal for difference between means: 7.2 to 31.7 l h(-1), P < 0.05).",Effect of troleandomycin on the pharmacokinetics of imipramine in Chinese: the role of CYP3A. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278210/),[hÂ·Î¼g] / [l],3134,54613,DB00458,Imipramine
,9278210,oral clearance,"Pretreatment with TAO significantly increased the AUC of IMI by 59% (1971 +/- 938 vs 3134 +/- 2000 microg l(-1) h, 95% confidence interval for difference between means: 218 to 2108 microg l(-1) h, P < 0.05) and decreased its oral clearance by 30% (60.9 +/- 27.4 vs 42.5 +/- 22.7 l h(-1), 95% confidence internal for difference between means: 7.2 to 31.7 l h(-1), P < 0.05).",Effect of troleandomycin on the pharmacokinetics of imipramine in Chinese: the role of CYP3A. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278210/),[l] / [h],60.9,54614,DB00458,Imipramine
,9278210,oral clearance,"Pretreatment with TAO significantly increased the AUC of IMI by 59% (1971 +/- 938 vs 3134 +/- 2000 microg l(-1) h, 95% confidence interval for difference between means: 218 to 2108 microg l(-1) h, P < 0.05) and decreased its oral clearance by 30% (60.9 +/- 27.4 vs 42.5 +/- 22.7 l h(-1), 95% confidence internal for difference between means: 7.2 to 31.7 l h(-1), P < 0.05).",Effect of troleandomycin on the pharmacokinetics of imipramine in Chinese: the role of CYP3A. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9278210/),[l] / [h],42.5,54615,DB00458,Imipramine
less,7834966,t1/2,"Among the SSRIs, there are a range of t1/2 values for the parent drugs, from relatively short t1/2 values of less than 24 hours (paroxetine, fluvoxamine) to among the longest found (e.g. 2 days for fluoxetine).",Pharmacokinetic optimisation of therapy with newer antidepressants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7834966/),h,24,56611,DB00458,Imipramine
,7834966,t1/2,"Among the SSRIs, there are a range of t1/2 values for the parent drugs, from relatively short t1/2 values of less than 24 hours (paroxetine, fluvoxamine) to among the longest found (e.g. 2 days for fluoxetine).",Pharmacokinetic optimisation of therapy with newer antidepressants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7834966/),d,2,56612,DB00458,Imipramine
,7834966,tmax,"All 3 of the structurally unique newer antidepressants [amfebutamone (bupropion), viloxazine venlafaxine] have relatively short tmax values (1 to 2 hours), which may relate to the early onset of adverse effects.",Pharmacokinetic optimisation of therapy with newer antidepressants. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7834966/),h,1 to 2,56613,DB00458,Imipramine
,16584282,terminal elimination half-life,Darifenacin was found to have a short terminal elimination half-life after intravenous and immediate-release oral dosage forms (3-4 hours) but this increased with a prolonged-release (PR) formulation (14-16 hours).,The clinical pharmacokinetics of darifenacin. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16584282/),h,3-4,57262,DB00458,Imipramine
,16584282,terminal elimination half-life,Darifenacin was found to have a short terminal elimination half-life after intravenous and immediate-release oral dosage forms (3-4 hours) but this increased with a prolonged-release (PR) formulation (14-16 hours).,The clinical pharmacokinetics of darifenacin. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16584282/),h,14-16,57263,DB00458,Imipramine
,16584282,absolute bioavailability,"The absolute bioavailability of darifenacin from 7.5 and 15 mg PR tablets was estimated to be 15.4% and 18.6%, respectively.",The clinical pharmacokinetics of darifenacin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16584282/),%,15.4,57264,DB00458,Imipramine
,16584282,absolute bioavailability,"The absolute bioavailability of darifenacin from 7.5 and 15 mg PR tablets was estimated to be 15.4% and 18.6%, respectively.",The clinical pharmacokinetics of darifenacin. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16584282/),%,18.6,57265,DB00458,Imipramine
,16584282,plasma clearance,"From intravenous administration, it has been established that darifenacin possesses a moderate-to-high hepatic extraction ratio, with high plasma clearance (36-52 L/h) and a volume of distribution (165-276L) that exceeds total body water.",The clinical pharmacokinetics of darifenacin. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16584282/),[l] / [h],36-52,57266,DB00458,Imipramine
,16584282,volume of distribution,"From intravenous administration, it has been established that darifenacin possesses a moderate-to-high hepatic extraction ratio, with high plasma clearance (36-52 L/h) and a volume of distribution (165-276L) that exceeds total body water.",The clinical pharmacokinetics of darifenacin. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16584282/),l,165-276,57267,DB00458,Imipramine
,3350999,total active compounds,The average of total active compounds in smokers (239 ng/ml) was less (p less than 0.1) than in nonsmokers (524 ng/ml).,Multiple-dose pharmacokinetics of imipramine and its major active and conjugated metabolites in depressed patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3350999/),[ng] / [ml],239,58686,DB00458,Imipramine
,3350999,total active compounds,The average of total active compounds in smokers (239 ng/ml) was less (p less than 0.1) than in nonsmokers (524 ng/ml).,Multiple-dose pharmacokinetics of imipramine and its major active and conjugated metabolites in depressed patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3350999/),[ng] / [ml],524,58687,DB00458,Imipramine
,3350999,serum concentration ratios,"The mean serum concentration ratios were 0.24 for 2-OH-IMI/IMI and 0.50 for 2-OH-DMI/DMI ratios, whereas the DMI/IMI ratio was 1.88, indicating more extensive accumulation of DMI.",Multiple-dose pharmacokinetics of imipramine and its major active and conjugated metabolites in depressed patients. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3350999/),,0.24,58688,DB00458,Imipramine
,3350999,serum concentration ratios,"The mean serum concentration ratios were 0.24 for 2-OH-IMI/IMI and 0.50 for 2-OH-DMI/DMI ratios, whereas the DMI/IMI ratio was 1.88, indicating more extensive accumulation of DMI.",Multiple-dose pharmacokinetics of imipramine and its major active and conjugated metabolites in depressed patients. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3350999/),,0.50,58689,DB00458,Imipramine
,3350999,serum concentration ratios,Appreciable glucuronide conjugate accumulation occurred with average serum concentration ratios of 8.13 for GA-O-IMI/2-OH-IMI and 6.22 for GA-O-DMI/2-OH-DMI.,Multiple-dose pharmacokinetics of imipramine and its major active and conjugated metabolites in depressed patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3350999/),,8.13,58690,DB00458,Imipramine
,3350999,serum concentration ratios,Appreciable glucuronide conjugate accumulation occurred with average serum concentration ratios of 8.13 for GA-O-IMI/2-OH-IMI and 6.22 for GA-O-DMI/2-OH-DMI.,Multiple-dose pharmacokinetics of imipramine and its major active and conjugated metabolites in depressed patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3350999/),,6.22,58691,DB00458,Imipramine
,3350999,Renal clearances,"Renal clearances of 2-OH-DMI were 35 to 267 ml/min, whereas those of the conjugates were only 10 to 110 ml/min.",Multiple-dose pharmacokinetics of imipramine and its major active and conjugated metabolites in depressed patients. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3350999/),[ml] / [min],35 to 267,58692,DB00458,Imipramine
,3350999,Renal clearances,"Renal clearances of 2-OH-DMI were 35 to 267 ml/min, whereas those of the conjugates were only 10 to 110 ml/min.",Multiple-dose pharmacokinetics of imipramine and its major active and conjugated metabolites in depressed patients. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3350999/),[ml] / [min],10 to 110,58693,DB00458,Imipramine
,8688885,brain/plasma AUC ratio,The brain/plasma AUC ratio after a single dose amounted to 28.72 for promazine and 12.78 for imipramine.,The pharmacokinetics of promazine and its metabolites after acute and chronic administration to rats--a comparison with the pharmacokinetics of imipramine. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8688885/),,28.72,60564,DB00458,Imipramine
,8688885,brain/plasma AUC ratio,The brain/plasma AUC ratio after a single dose amounted to 28.72 for promazine and 12.78 for imipramine.,The pharmacokinetics of promazine and its metabolites after acute and chronic administration to rats--a comparison with the pharmacokinetics of imipramine. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8688885/),,12.78,60565,DB00458,Imipramine
less,6436888,total elution time,The total elution time was less than 15 min.,"Quantification of imipramine and its major metabolites in whole blood, brain, and other tissues of the rat by liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6436888/),min,15,64324,DB00458,Imipramine
,8513649,peak plasma concentration,"After single 1 mg oral doses in humans, typical pharmacokinetic variables for alprazolam are: a peak plasma concentration 12 to 22 micrograms/L occurring 0.7 to 1.8h postdose, a volume of distribution of 0.8 to 1.3 L/kg, elimination half-life of 9 to 16h and clearance of 0.7 to 1.5 ml/min/kg.",Clinical pharmacokinetics of alprazolam. Therapeutic implications. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513649/),[Î¼g] / [l],12 to 22,68577,DB00458,Imipramine
,8513649,volume of distribution,"After single 1 mg oral doses in humans, typical pharmacokinetic variables for alprazolam are: a peak plasma concentration 12 to 22 micrograms/L occurring 0.7 to 1.8h postdose, a volume of distribution of 0.8 to 1.3 L/kg, elimination half-life of 9 to 16h and clearance of 0.7 to 1.5 ml/min/kg.",Clinical pharmacokinetics of alprazolam. Therapeutic implications. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513649/),[l] / [kg],0.8 to 1.3,68578,DB00458,Imipramine
,8513649,elimination half-life,"After single 1 mg oral doses in humans, typical pharmacokinetic variables for alprazolam are: a peak plasma concentration 12 to 22 micrograms/L occurring 0.7 to 1.8h postdose, a volume of distribution of 0.8 to 1.3 L/kg, elimination half-life of 9 to 16h and clearance of 0.7 to 1.5 ml/min/kg.",Clinical pharmacokinetics of alprazolam. Therapeutic implications. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513649/),h,9 to 16,68579,DB00458,Imipramine
,8513649,clearance,"After single 1 mg oral doses in humans, typical pharmacokinetic variables for alprazolam are: a peak plasma concentration 12 to 22 micrograms/L occurring 0.7 to 1.8h postdose, a volume of distribution of 0.8 to 1.3 L/kg, elimination half-life of 9 to 16h and clearance of 0.7 to 1.5 ml/min/kg.",Clinical pharmacokinetics of alprazolam. Therapeutic implications. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513649/),[ml] / [kgÂ·min],0.7 to 1.5,68580,DB00458,Imipramine
,8513649,Absolute bioavailability,Absolute bioavailability of oral alprazolam averages 80 to 100%.,Clinical pharmacokinetics of alprazolam. Therapeutic implications. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513649/),%,80 to 100,68581,DB00458,Imipramine
,8513649,steady-state plasma alpra,"Although a therapeutic concentration range is not clearly established, some studies indicate that optimal reduction of anxiety associated with panic disorder occurs at steady-state plasma alprazolam concentrations of 20 to 40 micrograms/L.",Clinical pharmacokinetics of alprazolam. Therapeutic implications. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8513649/),[Î¼g] / [l],20 to 40,68582,DB00458,Imipramine
,8075879,intracerebral,3. The intracerebral half life (t1/2) of Imip was 2.4 +/- 0.3 h with Imip alone.,Measurement and pharmacokinetic analysis of imipramine and its metabolite by brain microdialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8075879/),h,2.4,75126,DB00458,Imipramine
,8075879,half life (t1/2),3. The intracerebral half life (t1/2) of Imip was 2.4 +/- 0.3 h with Imip alone.,Measurement and pharmacokinetic analysis of imipramine and its metabolite by brain microdialysis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8075879/),h,2.4,75127,DB00458,Imipramine
,1277478,peak drug concentrations,"For both amines, the detection limit is 0.3 mug/liter; Six healthy volunteers who received a single oral dose of 50 mg of clomipramine hydrochloride showed peak drug concentrations in the blood 3 to 5 h after administration, ranging between 14.4 and 30.1 mug/liter.","Measurement of clomipramine, N-desmethyl-clomipramine, imipramine, and dehydroimipramine in biological fluids by selective ion monitoring, and pharmacokinetics of clomipramine. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1277478/),[Î¼g] / [l],14.4 and 30.1,75235,DB00458,Imipramine
,1277478,Plasma/whole blood concentration ratios,"Plasma/whole blood concentration ratios varied from 0.70 to 1.20, and the cumulative renal elimination from 0 to 72 h is less than 0.2% of the dose.","Measurement of clomipramine, N-desmethyl-clomipramine, imipramine, and dehydroimipramine in biological fluids by selective ion monitoring, and pharmacokinetics of clomipramine. ",Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1277478/),,0.70 to 1.20,75236,DB00458,Imipramine
,23677717,recovery,"The mean recovery values for KR-66344 and imipramine were 83.8 and 86.2%, respectively.","Determination of 2-(3-benzoyl)-4-hydroxy-1,1-dioxo-2H-1,2-benzothiazine-2-yl-1-phenylethanone by liquid chromatography-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23677717/),%,83.8,81550,DB00458,Imipramine
,23677717,recovery,"The mean recovery values for KR-66344 and imipramine were 83.8 and 86.2%, respectively.","Determination of 2-(3-benzoyl)-4-hydroxy-1,1-dioxo-2H-1,2-benzothiazine-2-yl-1-phenylethanone by liquid chromatography-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23677717/),%,86.2,81551,DB00458,Imipramine
,3792426,t 1/2,Cimetidine preadministration statistically prolonged imipramine t 1/2 compared to ranitidine (22.7 vs. 13.0 h) or placebo (10.8 h).,The effect of ranitidine and cimetidine on imipramine disposition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3792426/),h,22.7,82118,DB00458,Imipramine
,3792426,t 1/2,Cimetidine preadministration statistically prolonged imipramine t 1/2 compared to ranitidine (22.7 vs. 13.0 h) or placebo (10.8 h).,The effect of ranitidine and cimetidine on imipramine disposition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3792426/),h,13.0,82119,DB00458,Imipramine
,3792426,t 1/2,Cimetidine preadministration statistically prolonged imipramine t 1/2 compared to ranitidine (22.7 vs. 13.0 h) or placebo (10.8 h).,The effect of ranitidine and cimetidine on imipramine disposition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3792426/),h,10.8,82120,DB00458,Imipramine
,3792426,area under the curve (AUC),Mean imipramine area under the curve (AUC) following cimetidine pretreatment was more than double that following placebo (2.633 vs. 0.966 micrograms X h X ml-1) or ranitidine (1.14 micrograms X h X ml-1) pretreatment.,The effect of ranitidine and cimetidine on imipramine disposition. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3792426/),[hÂ·Î¼g] / [ml],2.633,82121,DB00458,Imipramine
,3792426,area under the curve (AUC),Mean imipramine area under the curve (AUC) following cimetidine pretreatment was more than double that following placebo (2.633 vs. 0.966 micrograms X h X ml-1) or ranitidine (1.14 micrograms X h X ml-1) pretreatment.,The effect of ranitidine and cimetidine on imipramine disposition. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3792426/),[hÂ·Î¼g] / [ml],0.966,82122,DB00458,Imipramine
,3792426,area under the curve (AUC),Mean imipramine area under the curve (AUC) following cimetidine pretreatment was more than double that following placebo (2.633 vs. 0.966 micrograms X h X ml-1) or ranitidine (1.14 micrograms X h X ml-1) pretreatment.,The effect of ranitidine and cimetidine on imipramine disposition. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3792426/),[hÂ·Î¼g] / [ml],1.14,82123,DB00458,Imipramine
,11341404,area under the curve,"Value (mean +/- SD) for area under the curve was 3.9 +/- 0.7 h X microg/ml, whereas volume of distribution was 584 +/- 161.7 ml/kg, total body clearance was 522 +/- 102 ml/kg/h, and mean residence time was 1.8 +/- 0.6 hours.",Pharmacokinetics of imipramine in narcoleptic horses. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11341404/),[hÂ·Î¼g] / [ml],3.9,83511,DB00458,Imipramine
,11341404,volume of distribution,"Value (mean +/- SD) for area under the curve was 3.9 +/- 0.7 h X microg/ml, whereas volume of distribution was 584 +/- 161.7 ml/kg, total body clearance was 522 +/- 102 ml/kg/h, and mean residence time was 1.8 +/- 0.6 hours.",Pharmacokinetics of imipramine in narcoleptic horses. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11341404/),[ml] / [kg],584,83512,DB00458,Imipramine
,11341404,total body clearance,"Value (mean +/- SD) for area under the curve was 3.9 +/- 0.7 h X microg/ml, whereas volume of distribution was 584 +/- 161.7 ml/kg, total body clearance was 522 +/- 102 ml/kg/h, and mean residence time was 1.8 +/- 0.6 hours.",Pharmacokinetics of imipramine in narcoleptic horses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11341404/),[ml] / [hÂ·kg],522,83513,DB00458,Imipramine
,11341404,mean residence time,"Value (mean +/- SD) for area under the curve was 3.9 +/- 0.7 h X microg/ml, whereas volume of distribution was 584 +/- 161.7 ml/kg, total body clearance was 522 +/- 102 ml/kg/h, and mean residence time was 1.8 +/- 0.6 hours.",Pharmacokinetics of imipramine in narcoleptic horses. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11341404/),h,1.8,83514,DB00458,Imipramine
,6429693,volume of distribution,"After IV administration, mean kinetic variables were: volume of distribution, 21.0 l/kg; total clearance, 12.8 ml/min per kg, and elimination half-life, 21.",Absolute bioavailability of imipramine: influence of food. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6429693/),[l] / [kg],21.0,83924,DB00458,Imipramine
,6429693,total clearance,"After IV administration, mean kinetic variables were: volume of distribution, 21.0 l/kg; total clearance, 12.8 ml/min per kg, and elimination half-life, 21.",Absolute bioavailability of imipramine: influence of food. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6429693/),[ml] / [kgÂ·min],12.8,83925,DB00458,Imipramine
,6429693,elimination half-life,"After IV administration, mean kinetic variables were: volume of distribution, 21.0 l/kg; total clearance, 12.8 ml/min per kg, and elimination half-life, 21.",Absolute bioavailability of imipramine: influence of food. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6429693/),,21,83926,DB00458,Imipramine
,6429693,absolute bioavailability,Mean absolute bioavailability of IMI in the fasting state was 43.6%.,Absolute bioavailability of imipramine: influence of food. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6429693/),%,43.6,83927,DB00458,Imipramine
,6429693,absolute bioavailability,"When IMI was administered immediately after the standardized meal, absolute bioavailability was 44.1%.",Absolute bioavailability of imipramine: influence of food. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6429693/),%,44.1,83928,DB00458,Imipramine
,6429693,time to peak IMI level,"After oral administration, the time to peak IMI level was not changed by concurrent food ingestion (2.8 vs 3.2 h after dosage), and the peak IMI concentration was no different (35 vs 30 ng/ml).",Absolute bioavailability of imipramine: influence of food. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6429693/),h,2.8,83929,DB00458,Imipramine
,6429693,time to peak IMI level,"After oral administration, the time to peak IMI level was not changed by concurrent food ingestion (2.8 vs 3.2 h after dosage), and the peak IMI concentration was no different (35 vs 30 ng/ml).",Absolute bioavailability of imipramine: influence of food. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6429693/),h,3.2,83930,DB00458,Imipramine
,6429693,peak IMI concentration,"After oral administration, the time to peak IMI level was not changed by concurrent food ingestion (2.8 vs 3.2 h after dosage), and the peak IMI concentration was no different (35 vs 30 ng/ml).",Absolute bioavailability of imipramine: influence of food. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6429693/),[ng] / [ml],35,83931,DB00458,Imipramine
,6429693,peak IMI concentration,"After oral administration, the time to peak IMI level was not changed by concurrent food ingestion (2.8 vs 3.2 h after dosage), and the peak IMI concentration was no different (35 vs 30 ng/ml).",Absolute bioavailability of imipramine: influence of food. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6429693/),[ng] / [ml],30,83932,DB00458,Imipramine
,18175970,flow rate,"Chromatographic separation was achieved isocratically on a C18 reversed-phase column within 3.0 min, using a mobile phase of acetonitrile-10 mM ammonium formate (90 : 10 v/v) at a flow rate of 0.3 ml/min.",Development and validation of LC-MS/MS method for the quantification of oxcarbazepine in human plasma using an experimental design. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18175970/),[ml] / [min],0.3,87504,DB00458,Imipramine
>,18175970,m/z,Quantitation was achieved using multiple reaction monitoring (MRM) scan at MRM transitions m/z 253>208 and m/z 281>86 for OXB and the IS respectively.,Development and validation of LC-MS/MS method for the quantification of oxcarbazepine in human plasma using an experimental design. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18175970/),,253,87505,DB00458,Imipramine
>,18175970,m/z,Quantitation was achieved using multiple reaction monitoring (MRM) scan at MRM transitions m/z 253>208 and m/z 281>86 for OXB and the IS respectively.,Development and validation of LC-MS/MS method for the quantification of oxcarbazepine in human plasma using an experimental design. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18175970/),,208,87506,DB00458,Imipramine
>,18175970,m/z 281,Quantitation was achieved using multiple reaction monitoring (MRM) scan at MRM transitions m/z 253>208 and m/z 281>86 for OXB and the IS respectively.,Development and validation of LC-MS/MS method for the quantification of oxcarbazepine in human plasma using an experimental design. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18175970/),,86,87507,DB00458,Imipramine
,18175970,recoveries,Analytical recoveries of OXB from spiked human plasma were in the range of 74.9 to 76.3%.,Development and validation of LC-MS/MS method for the quantification of oxcarbazepine in human plasma using an experimental design. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18175970/),%,74.9 to 76.3,87508,DB00458,Imipramine
,7795822,flow-rate,"Chromatography was performed isocratically with acetonitrile-methanol-0.05 M KH2PO4 (20:25:55, v/v) at pH 3.0 containing 3% triethylamine at a flow-rate of 1 ml/min.",Determination of ticlopidine in human plasma by high-performance liquid chromatography and ultraviolet absorbance detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7795822/),[ml] / [min],1,88995,DB00458,Imipramine
,8085287,plasma IP,"Initial plasma IP level was 2260 ng/ml, whole blood total cyclosporine (T-CsA) concentration was 1,800 ng/ml and that of specific cyclosporine (Sp-CsA), 714 ng/ml.",Multiple drug overdose in a kidney transplant patient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8085287/),[ng] / [ml],714,90235,DB00458,Imipramine
,8085287,concentration,"Five days after overdose, the IP concentration was 232 ng/ml, that of T-CsA 401 ng/ml, and that of Sp-CsA 96 ng/ml.",Multiple drug overdose in a kidney transplant patient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8085287/),[ng] / [ml],232,90236,DB00458,Imipramine
,8085287,concentration,"Five days after overdose, the IP concentration was 232 ng/ml, that of T-CsA 401 ng/ml, and that of Sp-CsA 96 ng/ml.",Multiple drug overdose in a kidney transplant patient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8085287/),[ng] / [ml],401,90237,DB00458,Imipramine
,8085287,concentration,"Five days after overdose, the IP concentration was 232 ng/ml, that of T-CsA 401 ng/ml, and that of Sp-CsA 96 ng/ml.",Multiple drug overdose in a kidney transplant patient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8085287/),[ng] / [ml],96,90238,DB00458,Imipramine
,8085287,t1/2,"Compared to subjects on therapeutic doses, a significant prolongation of the half-life, t 1/2, was observed for both IP (t1/2, 43.4 h) and Sp-CsA (t1/2, 70.1 h).",Multiple drug overdose in a kidney transplant patient. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8085287/),h,43.4,90239,DB00458,Imipramine
,8085287,t1/2,"Compared to subjects on therapeutic doses, a significant prolongation of the half-life, t 1/2, was observed for both IP (t1/2, 43.4 h) and Sp-CsA (t1/2, 70.1 h).",Multiple drug overdose in a kidney transplant patient. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8085287/),h,70.1,90240,DB00458,Imipramine
,11510628,time to reach maximum observed plasma concentration,"In pharmacokinetic studies in humans, quetiapine was rapidly absorbed after oral administration, with median time to reach maximum observed plasma concentration ranging from 1 to 2 hours.",Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11510628/),h,1 to 2,91263,DB00458,Imipramine
,11510628,terminal half-life,The drug is eliminated with a mean terminal half-life of approximately 7 hours.,Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11510628/),h,7,91264,DB00458,Imipramine
,7032872,elimination half-life,Trazodone is excreted primarily as metabolites by the kidneys and possesses a biphasic elimination half-life of 4.4 hours for the first 10 hours and 7.5 hours for the next 24 hours.,"Trazodone (Desyrel, Mead-Johnson Pharmaceutical Division). ","t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7032872/),h,4.4,93210,DB00458,Imipramine
,7032872,elimination half-life,Trazodone is excreted primarily as metabolites by the kidneys and possesses a biphasic elimination half-life of 4.4 hours for the first 10 hours and 7.5 hours for the next 24 hours.,"Trazodone (Desyrel, Mead-Johnson Pharmaceutical Division). ","t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7032872/),h,7.5,93211,DB00458,Imipramine
,6636256,Absolute recoveries,Absolute recoveries were 87-97%.,Liquid chromatographic separation of antidepressant drugs: I. Tricyclics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6636256/),%,87-97,96511,DB00458,Imipramine
,6636256,Detection limits,"Detection limits under the conditions described were 2 ng/ml for AMI, DOX, and IMI, 4 ng/ml for NORT, DESDOX, and DESIP, and 10 ng/ml for PRO.",Liquid chromatographic separation of antidepressant drugs: I. Tricyclics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6636256/),[ng] / [ml],2,96512,DB00458,Imipramine
,6636256,Detection limits,"Detection limits under the conditions described were 2 ng/ml for AMI, DOX, and IMI, 4 ng/ml for NORT, DESDOX, and DESIP, and 10 ng/ml for PRO.",Liquid chromatographic separation of antidepressant drugs: I. Tricyclics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6636256/),[ng] / [ml],4,96513,DB00458,Imipramine
,6636256,Detection limits,"Detection limits under the conditions described were 2 ng/ml for AMI, DOX, and IMI, 4 ng/ml for NORT, DESDOX, and DESIP, and 10 ng/ml for PRO.",Liquid chromatographic separation of antidepressant drugs: I. Tricyclics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6636256/),[ng] / [ml],10,96514,DB00458,Imipramine
less,6636256,total assay time,The total assay time was less than 10 min for DESIP and 12 min for PRO.,Liquid chromatographic separation of antidepressant drugs: I. Tricyclics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6636256/),min,10,96515,DB00458,Imipramine
,6636256,total assay time,The total assay time was less than 10 min for DESIP and 12 min for PRO.,Liquid chromatographic separation of antidepressant drugs: I. Tricyclics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6636256/),min,12,96516,DB00458,Imipramine
,2792169,maximum concentrations,2-OH-Imipramine and 2-OH-desipramine were detected in plasma before (maximum concentrations 30-100 nmol.l-1) but not during quinidine.,Quinidine inhibits the 2-hydroxylation of imipramine and desipramine but not the demethylation of imipramine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2792169/),[nM] / [l],30-100,97307,DB00458,Imipramine
,6734030,clearance,"After intravenous injection, volume of distribution was much the same in the OCS and control groups and clearance was of the same order (899 and 975 ml/min).",Imipramine disposition in users of oral contraceptive steroids. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6734030/),[ml] / [min],899,100398,DB00458,Imipramine
,6734030,clearance,"After intravenous injection, volume of distribution was much the same in the OCS and control groups and clearance was of the same order (899 and 975 ml/min).",Imipramine disposition in users of oral contraceptive steroids. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6734030/),[ml] / [min],975,100399,DB00458,Imipramine
,6734030,Elimination t1/2,Elimination t1/2 was prolonged in OCS users after intravenous doses (17.8 vs 25.5 hr) but did not change after oral doses (18.4 vs 19.1 hr).,Imipramine disposition in users of oral contraceptive steroids. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6734030/),h,17.8,100400,DB00458,Imipramine
,6734030,Elimination t1/2,Elimination t1/2 was prolonged in OCS users after intravenous doses (17.8 vs 25.5 hr) but did not change after oral doses (18.4 vs 19.1 hr).,Imipramine disposition in users of oral contraceptive steroids. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6734030/),h,25.5,100401,DB00458,Imipramine
,6734030,Elimination t1/2,Elimination t1/2 was prolonged in OCS users after intravenous doses (17.8 vs 25.5 hr) but did not change after oral doses (18.4 vs 19.1 hr).,Imipramine disposition in users of oral contraceptive steroids. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6734030/),h,18.4,100402,DB00458,Imipramine
,6734030,Elimination t1/2,Elimination t1/2 was prolonged in OCS users after intravenous doses (17.8 vs 25.5 hr) but did not change after oral doses (18.4 vs 19.1 hr).,Imipramine disposition in users of oral contraceptive steroids. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6734030/),h,19.1,100403,DB00458,Imipramine
,6734030,Absolute bioavailability,"Absolute bioavailability increased in OCS users (from 27.1% vs 44.1%), which resulted in a trend toward decreased apparent oral clearance (from 4649 vs 2322 ml/min).",Imipramine disposition in users of oral contraceptive steroids. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6734030/),%,27.1,100404,DB00458,Imipramine
,6734030,Absolute bioavailability,"Absolute bioavailability increased in OCS users (from 27.1% vs 44.1%), which resulted in a trend toward decreased apparent oral clearance (from 4649 vs 2322 ml/min).",Imipramine disposition in users of oral contraceptive steroids. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6734030/),%,44.1,100405,DB00458,Imipramine
,6734030,apparent oral clearance,"Absolute bioavailability increased in OCS users (from 27.1% vs 44.1%), which resulted in a trend toward decreased apparent oral clearance (from 4649 vs 2322 ml/min).",Imipramine disposition in users of oral contraceptive steroids. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6734030/),[ml] / [min],4649,100406,DB00458,Imipramine
,6734030,apparent oral clearance,"Absolute bioavailability increased in OCS users (from 27.1% vs 44.1%), which resulted in a trend toward decreased apparent oral clearance (from 4649 vs 2322 ml/min).",Imipramine disposition in users of oral contraceptive steroids. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6734030/),[ml] / [min],2322,100407,DB00458,Imipramine
,11430636,relative bioavailabilities,"The relative bioavailabilities of Tofranil 25 and Tofranil mite were 97% and 81%, respectively.",Relative bioavailability of imipramine (Tofranil) coated tablets in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11430636/),%,97,111212,DB00458,Imipramine
,11430636,relative bioavailabilities,"The relative bioavailabilities of Tofranil 25 and Tofranil mite were 97% and 81%, respectively.",Relative bioavailability of imipramine (Tofranil) coated tablets in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11430636/),%,81,111213,DB00458,Imipramine
,8333005,half-life,"Compared with a control session, treatment with fluvoxamine caused a significant prolongation of imipramine half-life (from 22.8 +/- 6.4 to 40.5 +/- 5.0 h, means +/- SD, p < 0.01) and a marked decrease in imipramine apparent oral clearance (from 1.02 +/- 0.19 to 0.28 +/- 0.06 L/h/kg, p < 0.0001).",Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8333005/),h,22.8,113388,DB00458,Imipramine
,8333005,half-life,"Compared with a control session, treatment with fluvoxamine caused a significant prolongation of imipramine half-life (from 22.8 +/- 6.4 to 40.5 +/- 5.0 h, means +/- SD, p < 0.01) and a marked decrease in imipramine apparent oral clearance (from 1.02 +/- 0.19 to 0.28 +/- 0.06 L/h/kg, p < 0.0001).",Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8333005/),h,40.5,113389,DB00458,Imipramine
,8333005,apparent oral clearance,"Compared with a control session, treatment with fluvoxamine caused a significant prolongation of imipramine half-life (from 22.8 +/- 6.4 to 40.5 +/- 5.0 h, means +/- SD, p < 0.01) and a marked decrease in imipramine apparent oral clearance (from 1.02 +/- 0.19 to 0.28 +/- 0.06 L/h/kg, p < 0.0001).",Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8333005/),[l] / [hÂ·kg],1.02,113390,DB00458,Imipramine
,8333005,apparent oral clearance,"Compared with a control session, treatment with fluvoxamine caused a significant prolongation of imipramine half-life (from 22.8 +/- 6.4 to 40.5 +/- 5.0 h, means +/- SD, p < 0.01) and a marked decrease in imipramine apparent oral clearance (from 1.02 +/- 0.19 to 0.28 +/- 0.06 L/h/kg, p < 0.0001).",Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8333005/),[l] / [hÂ·kg],0.28,113391,DB00458,Imipramine
,27079250,t1/2,"The present account is a summary of our in vitro studies on the facile oxidative desulfurization in compound 1 to a cyclic ether metabolite M1 [5-(2,4-dimethoxyphenyl)-2,3-dihydro-7H-oxazolo[3,2-a]pyrimidin-7-one] in NADPH-supplemented rats (t1/2 [half-life = mean Â± S.D.] = 8.6 Â± 0.4 minutes) and dog liver microsomes (t1/2 = 11.2 Â± 0.4 minutes), but not in human liver microsomes (t1/2 > 120 minutes).",Species Differences in the Oxidative Desulfurization of a Thiouracil-Based Irreversible Myeloperoxidase Inactivator by Flavin-Containing Monooxygenase Enzymes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27079250/),min,8.6,119885,DB00458,Imipramine
,27079250,t1/2,"The present account is a summary of our in vitro studies on the facile oxidative desulfurization in compound 1 to a cyclic ether metabolite M1 [5-(2,4-dimethoxyphenyl)-2,3-dihydro-7H-oxazolo[3,2-a]pyrimidin-7-one] in NADPH-supplemented rats (t1/2 [half-life = mean Â± S.D.] = 8.6 Â± 0.4 minutes) and dog liver microsomes (t1/2 = 11.2 Â± 0.4 minutes), but not in human liver microsomes (t1/2 > 120 minutes).",Species Differences in the Oxidative Desulfurization of a Thiouracil-Based Irreversible Myeloperoxidase Inactivator by Flavin-Containing Monooxygenase Enzymes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27079250/),min,11.2,119886,DB00458,Imipramine
>,27079250,t1/2,"The present account is a summary of our in vitro studies on the facile oxidative desulfurization in compound 1 to a cyclic ether metabolite M1 [5-(2,4-dimethoxyphenyl)-2,3-dihydro-7H-oxazolo[3,2-a]pyrimidin-7-one] in NADPH-supplemented rats (t1/2 [half-life = mean Â± S.D.] = 8.6 Â± 0.4 minutes) and dog liver microsomes (t1/2 = 11.2 Â± 0.4 minutes), but not in human liver microsomes (t1/2 > 120 minutes).",Species Differences in the Oxidative Desulfurization of a Thiouracil-Based Irreversible Myeloperoxidase Inactivator by Flavin-Containing Monooxygenase Enzymes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27079250/),min,120,119887,DB00458,Imipramine
,27079250,Michaelis-Menten constant,"Oxidation by FMO1 followed Michaelis-Menten kinetics with Michaelis-Menten constant, maximum rate of oxidative desulfurization, and intrinsic clearance values of 209 Î¼M, 20.4 nmol/min/mg protein, and 82.7 Î¼l/min/mg protein, respectively.",Species Differences in the Oxidative Desulfurization of a Thiouracil-Based Irreversible Myeloperoxidase Inactivator by Flavin-Containing Monooxygenase Enzymes. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27079250/),Î¼M,209,119888,DB00458,Imipramine
,27079250,maximum rate of oxidative desulfurization,"Oxidation by FMO1 followed Michaelis-Menten kinetics with Michaelis-Menten constant, maximum rate of oxidative desulfurization, and intrinsic clearance values of 209 Î¼M, 20.4 nmol/min/mg protein, and 82.7 Î¼l/min/mg protein, respectively.",Species Differences in the Oxidative Desulfurization of a Thiouracil-Based Irreversible Myeloperoxidase Inactivator by Flavin-Containing Monooxygenase Enzymes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27079250/),[nM] / [mgÂ·min],20.4,119889,DB00458,Imipramine
,27079250,intrinsic clearance,"Oxidation by FMO1 followed Michaelis-Menten kinetics with Michaelis-Menten constant, maximum rate of oxidative desulfurization, and intrinsic clearance values of 209 Î¼M, 20.4 nmol/min/mg protein, and 82.7 Î¼l/min/mg protein, respectively.",Species Differences in the Oxidative Desulfurization of a Thiouracil-Based Irreversible Myeloperoxidase Inactivator by Flavin-Containing Monooxygenase Enzymes. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27079250/),[Î¼l] / [mgÂ·min],82.7,119890,DB00458,Imipramine
,1505617,elimination constant,"The mean value of the elimination constant of the drug and metabolite were 0.0425 h-1 and 0.0359, h-1 respectively.",Population pharmacokinetics of imipramine in children. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1505617/),1/[h],0.0425,123947,DB00458,Imipramine
,1505617,elimination constant,"The mean value of the elimination constant of the drug and metabolite were 0.0425 h-1 and 0.0359, h-1 respectively.",Population pharmacokinetics of imipramine in children. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1505617/),1/[h],0.0359,123948,DB00458,Imipramine
,8521677,absolute bio-availability,Zolpidem is approximately 92% bound to plasma proteins; absolute bio-availability of zolpidem is about 70%.,Clinical pharmacokinetics and pharmacodynamics of zolpidem. Therapeutic implications. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8521677/),%,70,127592,DB00458,Imipramine
,8521677,peak plasma concentration,"After single 20mg oral doses, typical values of pharmacokinetic variables for zolpidem in humans are: a peak plasma concentration of 192 to 324 micrograms/L occurring 0.75 to 2.6 hours postdose; a terminal elimination half-line of 1.5 to 3.2 hours; and total clearance of 0.24 to 0.27 ml/min/kg.",Clinical pharmacokinetics and pharmacodynamics of zolpidem. Therapeutic implications. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8521677/),[Î¼g] / [l],192 to 324,127593,DB00458,Imipramine
,8521677,terminal elimination half-line,"After single 20mg oral doses, typical values of pharmacokinetic variables for zolpidem in humans are: a peak plasma concentration of 192 to 324 micrograms/L occurring 0.75 to 2.6 hours postdose; a terminal elimination half-line of 1.5 to 3.2 hours; and total clearance of 0.24 to 0.27 ml/min/kg.",Clinical pharmacokinetics and pharmacodynamics of zolpidem. Therapeutic implications. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8521677/),h,1.5 to 3.2,127594,DB00458,Imipramine
,8521677,total clearance,"After single 20mg oral doses, typical values of pharmacokinetic variables for zolpidem in humans are: a peak plasma concentration of 192 to 324 micrograms/L occurring 0.75 to 2.6 hours postdose; a terminal elimination half-line of 1.5 to 3.2 hours; and total clearance of 0.24 to 0.27 ml/min/kg.",Clinical pharmacokinetics and pharmacodynamics of zolpidem. Therapeutic implications. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8521677/),[ml] / [kgÂ·min],0.24 to 0.27,127595,DB00458,Imipramine
,10511917,half-life,"Its mean half-life in healthy individuals was 33 hours, ranging from 21 to 54 hours.",Olanzapine. Pharmacokinetic and pharmacodynamic profile. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10511917/),h,33,129674,DB00458,Imipramine
,10511917,apparent plasma clearance,"The mean apparent plasma clearance was 26 L/h, ranging from 12 to 47 L/h.",Olanzapine. Pharmacokinetic and pharmacodynamic profile. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10511917/),[l] / [h],26,129675,DB00458,Imipramine
,21466936,m/,"The ion transitions monitored were m/z 553.2â206.2 for KR-66223, m/z 281.3â86.1 for imipramine in multiple reaction monitoring (MRM) mode.","Determination of a dipeptidyl peptidase IV agonist, Î²-aminoacyl containing thiazolidine derivatives (KR-66223) in rat plasma by liquid chromatography-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21466936/),,553.2,137210,DB00458,Imipramine
,21466936,m/,"The ion transitions monitored were m/z 553.2â206.2 for KR-66223, m/z 281.3â86.1 for imipramine in multiple reaction monitoring (MRM) mode.","Determination of a dipeptidyl peptidase IV agonist, Î²-aminoacyl containing thiazolidine derivatives (KR-66223) in rat plasma by liquid chromatography-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21466936/),,206.2,137211,DB00458,Imipramine
,21466936,m/z,"The ion transitions monitored were m/z 553.2â206.2 for KR-66223, m/z 281.3â86.1 for imipramine in multiple reaction monitoring (MRM) mode.","Determination of a dipeptidyl peptidase IV agonist, Î²-aminoacyl containing thiazolidine derivatives (KR-66223) in rat plasma by liquid chromatography-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21466936/),,281.3,137212,DB00458,Imipramine
,21466936,m/z,"The ion transitions monitored were m/z 553.2â206.2 for KR-66223, m/z 281.3â86.1 for imipramine in multiple reaction monitoring (MRM) mode.","Determination of a dipeptidyl peptidase IV agonist, Î²-aminoacyl containing thiazolidine derivatives (KR-66223) in rat plasma by liquid chromatography-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21466936/),,86.1,137213,DB00458,Imipramine
,21466936,recovery,"The average recovery was 78.9% and 87.1% from rat plasma for KR-66223 and imipramine, respectively.","Determination of a dipeptidyl peptidase IV agonist, Î²-aminoacyl containing thiazolidine derivatives (KR-66223) in rat plasma by liquid chromatography-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21466936/),%,78.9,137214,DB00458,Imipramine
,21466936,recovery,"The average recovery was 78.9% and 87.1% from rat plasma for KR-66223 and imipramine, respectively.","Determination of a dipeptidyl peptidase IV agonist, Î²-aminoacyl containing thiazolidine derivatives (KR-66223) in rat plasma by liquid chromatography-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21466936/),%,87.1,137215,DB00458,Imipramine
,22357285,m/z,The ions m/z 501.2â207.2 for TM-25659 and m/z 281.0â86.0 for imipramine in multiple reaction monitoring mode were used for the quantitation.,"Determination of a novel TAZ modulator, 2-butyl-5-methyl-6-(pyridine-3-yl)-3-[2'-(1H-tetrazole-5-yl)-biphenyl-4-ylmethyl]-3H imidazo[4,5-b]pyridine] (TM-25659) in rat plasma by liquid chromatography-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22357285/),,501.2,139570,DB00458,Imipramine
,22357285,m/z,The ions m/z 501.2â207.2 for TM-25659 and m/z 281.0â86.0 for imipramine in multiple reaction monitoring mode were used for the quantitation.,"Determination of a novel TAZ modulator, 2-butyl-5-methyl-6-(pyridine-3-yl)-3-[2'-(1H-tetrazole-5-yl)-biphenyl-4-ylmethyl]-3H imidazo[4,5-b]pyridine] (TM-25659) in rat plasma by liquid chromatography-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22357285/),,207.2,139571,DB00458,Imipramine
,22357285,m/z,The ions m/z 501.2â207.2 for TM-25659 and m/z 281.0â86.0 for imipramine in multiple reaction monitoring mode were used for the quantitation.,"Determination of a novel TAZ modulator, 2-butyl-5-methyl-6-(pyridine-3-yl)-3-[2'-(1H-tetrazole-5-yl)-biphenyl-4-ylmethyl]-3H imidazo[4,5-b]pyridine] (TM-25659) in rat plasma by liquid chromatography-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22357285/),,281.0,139572,DB00458,Imipramine
,22357285,m/z,The ions m/z 501.2â207.2 for TM-25659 and m/z 281.0â86.0 for imipramine in multiple reaction monitoring mode were used for the quantitation.,"Determination of a novel TAZ modulator, 2-butyl-5-methyl-6-(pyridine-3-yl)-3-[2'-(1H-tetrazole-5-yl)-biphenyl-4-ylmethyl]-3H imidazo[4,5-b]pyridine] (TM-25659) in rat plasma by liquid chromatography-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22357285/),,86.0,139573,DB00458,Imipramine
,22357285,percent recoveries,"The percent recoveries of TM-25659 and imipramine were 98.6% and 95.7% from rat plasma, respectively.","Determination of a novel TAZ modulator, 2-butyl-5-methyl-6-(pyridine-3-yl)-3-[2'-(1H-tetrazole-5-yl)-biphenyl-4-ylmethyl]-3H imidazo[4,5-b]pyridine] (TM-25659) in rat plasma by liquid chromatography-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22357285/),%,98.6,139574,DB00458,Imipramine
,22357285,percent recoveries,"The percent recoveries of TM-25659 and imipramine were 98.6% and 95.7% from rat plasma, respectively.","Determination of a novel TAZ modulator, 2-butyl-5-methyl-6-(pyridine-3-yl)-3-[2'-(1H-tetrazole-5-yl)-biphenyl-4-ylmethyl]-3H imidazo[4,5-b]pyridine] (TM-25659) in rat plasma by liquid chromatography-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22357285/),%,95.7,139575,DB00458,Imipramine
,9868741,limit of detection,The limit of detection was 0.06 nmol.mg protein-1.hr-1.,Fluvoxamine is a potent inhibitor of the metabolism of caffeine in vitro. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9868741/),[-1Â·mgÂ·nM] / [h],0.06,140625,DB00458,Imipramine
,9868741,Ki,"As expected, fluvoxamine was a very potent inhibitor of the formation of the N-demethylated caffeine metabolites, displaying Ki values of 0.08-0.28 microM.",Fluvoxamine is a potent inhibitor of the metabolism of caffeine in vitro. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9868741/),Î¼M,0.08-0.28,140626,DB00458,Imipramine
,9868741,Kis,"The CYP3A4 inhibitors, ketoconazole and bromocriptine, inhibited 1,3,7-trimethyluric acid formation with Kis of 0.75 microM and 5 microM, respectively, thus further supporting the involvement of CYP3A4 in the 8-hydroxylation of caffeine.",Fluvoxamine is a potent inhibitor of the metabolism of caffeine in vitro. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9868741/),Î¼M,0.75,140627,DB00458,Imipramine
,9868741,Kis,"The CYP3A4 inhibitors, ketoconazole and bromocriptine, inhibited 1,3,7-trimethyluric acid formation with Kis of 0.75 microM and 5 microM, respectively, thus further supporting the involvement of CYP3A4 in the 8-hydroxylation of caffeine.",Fluvoxamine is a potent inhibitor of the metabolism of caffeine in vitro. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9868741/),Î¼M,5,140628,DB00458,Imipramine
,2359311,Total body clearance of unbound drug,"Total body clearance of unbound drug, as calculated from the plasma concentration versus time data, was significantly increased in the alcoholic group as compared to the control group (3.12 vs 1.51 L/hr/kg).",Intravenous pharmacokinetics of 2-hydroxyimipramine in alcoholics and normal controls. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2359311/),[l] / [hÂ·kg],3.12,141785,DB00458,Imipramine
,2359311,Total body clearance of unbound drug,"Total body clearance of unbound drug, as calculated from the plasma concentration versus time data, was significantly increased in the alcoholic group as compared to the control group (3.12 vs 1.51 L/hr/kg).",Intravenous pharmacokinetics of 2-hydroxyimipramine in alcoholics and normal controls. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2359311/),[l] / [hÂ·kg],1.51,141786,DB00458,Imipramine
,2359311,Terminal elimination half-life,Terminal elimination half-life was decreased in the alcoholics (7.07 vs 10.12 hr).,Intravenous pharmacokinetics of 2-hydroxyimipramine in alcoholics and normal controls. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2359311/),h,7.07,141787,DB00458,Imipramine
,2359311,Terminal elimination half-life,Terminal elimination half-life was decreased in the alcoholics (7.07 vs 10.12 hr).,Intravenous pharmacokinetics of 2-hydroxyimipramine in alcoholics and normal controls. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2359311/),h,10.12,141788,DB00458,Imipramine
up to,19540084,Loading capacity,Loading capacity up to 25 microl of extract injected on column showed no peak distortion.,Comparison of fused-core and conventional particle size columns by LC-MS/MS and UV: application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19540084/),Î¼l,25,145328,DB00458,Imipramine
,19540084,flow rate,The registered back-pressure from a flow rate of 1.0 ml/min did not exceed 3400 psi making it compatible with standard HPLC equipment (typically rated to 6000 psi).,Comparison of fused-core and conventional particle size columns by LC-MS/MS and UV: application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19540084/),[ml] / [min],1.0,145329,DB00458,Imipramine
not exceed,19540084,flow rate,The registered back-pressure from a flow rate of 1.0 ml/min did not exceed 3400 psi making it compatible with standard HPLC equipment (typically rated to 6000 psi).,Comparison of fused-core and conventional particle size columns by LC-MS/MS and UV: application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19540084/),psi,3400,145330,DB00458,Imipramine
,1102994,bioavailability,The bioavailability of an orally administered dose of imipramine ranged between 29.5 and 54.7%.,Plasma levels of imipramine and desipramine in man after different routes of administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1102994/),%,29.5 and 54.7,156590,DB00458,Imipramine
,1102994,half-lives,The half-lives of imipramine ranged from 4.0-17.6 hrs (M = 7.6 +/- 2.5) after single oral doses and between 9.2 and 20.2 hrs (M = 14.0 +/- 1.9) after multiple oral doses.,Plasma levels of imipramine and desipramine in man after different routes of administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1102994/),h,4.0-17.6,156591,DB00458,Imipramine
,1102994,half-lives,The half-lives of imipramine ranged from 4.0-17.6 hrs (M = 7.6 +/- 2.5) after single oral doses and between 9.2 and 20.2 hrs (M = 14.0 +/- 1.9) after multiple oral doses.,Plasma levels of imipramine and desipramine in man after different routes of administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1102994/),h,7.6,156592,DB00458,Imipramine
,1102994,half-lives,The half-lives of imipramine ranged from 4.0-17.6 hrs (M = 7.6 +/- 2.5) after single oral doses and between 9.2 and 20.2 hrs (M = 14.0 +/- 1.9) after multiple oral doses.,Plasma levels of imipramine and desipramine in man after different routes of administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1102994/),h,9.2 and 20.2,156593,DB00458,Imipramine
,1102994,half-lives,The half-lives of imipramine ranged from 4.0-17.6 hrs (M = 7.6 +/- 2.5) after single oral doses and between 9.2 and 20.2 hrs (M = 14.0 +/- 1.9) after multiple oral doses.,Plasma levels of imipramine and desipramine in man after different routes of administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1102994/),h,14.0,156594,DB00458,Imipramine
,1102994,half-lives,The half-lives of the formed desipramine ranged between 13.5 and 61.5 hrs (M = 29.9 +/- 8.7) after multiple oral doses of imipramine hydrochloride.,Plasma levels of imipramine and desipramine in man after different routes of administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1102994/),h,13.5 and 61.5,156595,DB00458,Imipramine
,1102994,half-lives,The half-lives of the formed desipramine ranged between 13.5 and 61.5 hrs (M = 29.9 +/- 8.7) after multiple oral doses of imipramine hydrochloride.,Plasma levels of imipramine and desipramine in man after different routes of administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1102994/),h,29.9,156596,DB00458,Imipramine
,1102994,steady-state plasma concentration,"The observed mean steady-state plasma concentration after multiple oral doses of imipramine hydrochloride, 50 mg t.i.d. varied from 21.4-69.0 mug/1 (M = 38.2 +/- 8.7) for imipramine and from 33.7-136.0 mug/1 (M 72.3 +/- 19.5) for desipramine.",Plasma levels of imipramine and desipramine in man after different routes of administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1102994/),Î¼g,21.4-69.0,156597,DB00458,Imipramine
,1102994,steady-state plasma concentration,"The observed mean steady-state plasma concentration after multiple oral doses of imipramine hydrochloride, 50 mg t.i.d. varied from 21.4-69.0 mug/1 (M = 38.2 +/- 8.7) for imipramine and from 33.7-136.0 mug/1 (M 72.3 +/- 19.5) for desipramine.",Plasma levels of imipramine and desipramine in man after different routes of administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1102994/),Î¼g,38.2,156598,DB00458,Imipramine
,1102994,steady-state plasma concentration,"The observed mean steady-state plasma concentration after multiple oral doses of imipramine hydrochloride, 50 mg t.i.d. varied from 21.4-69.0 mug/1 (M = 38.2 +/- 8.7) for imipramine and from 33.7-136.0 mug/1 (M 72.3 +/- 19.5) for desipramine.",Plasma levels of imipramine and desipramine in man after different routes of administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1102994/),Î¼g,33.7-136.0,156599,DB00458,Imipramine
,1102994,steady-state plasma concentration,"The observed mean steady-state plasma concentration after multiple oral doses of imipramine hydrochloride, 50 mg t.i.d. varied from 21.4-69.0 mug/1 (M = 38.2 +/- 8.7) for imipramine and from 33.7-136.0 mug/1 (M 72.3 +/- 19.5) for desipramine.",Plasma levels of imipramine and desipramine in man after different routes of administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1102994/),,72.3,156600,DB00458,Imipramine
,2867146,Vdss,In the control rats the Vdss of imipramine was large at 19.9 litre kg-1.,Effect of phenobarbitone on the distribution and elimination of imipramine in rats. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2867146/),[l] / [kg],19.9,157550,DB00458,Imipramine
less,2867146,urinary excretion ratios,"The urinary excretion ratios of imipramine and desipramine, to the dose of imipramine over 8 h, were less than 1.5% in both groups.",Effect of phenobarbitone on the distribution and elimination of imipramine in rats. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2867146/),%,1.5,157551,DB00458,Imipramine
,7395537,T 1/2 beta,"It was found that cystamine prevented changes in blood imipramine level in the irradiated animals but it protected additionally the process of drug elimination from the blood (T 1/2 beta in controls = 1.67 h, in irradiated = 2.38 h, in irradiated premedicated = 4.01 h).",Cystamine effect on the pharmacokinetics of imipramine in radiation sickness. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7395537/),h,1.67,161216,DB00458,Imipramine
,7395537,T 1/2 beta,"It was found that cystamine prevented changes in blood imipramine level in the irradiated animals but it protected additionally the process of drug elimination from the blood (T 1/2 beta in controls = 1.67 h, in irradiated = 2.38 h, in irradiated premedicated = 4.01 h).",Cystamine effect on the pharmacokinetics of imipramine in radiation sickness. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7395537/),h,2.38,161217,DB00458,Imipramine
,7395537,T 1/2 beta,"It was found that cystamine prevented changes in blood imipramine level in the irradiated animals but it protected additionally the process of drug elimination from the blood (T 1/2 beta in controls = 1.67 h, in irradiated = 2.38 h, in irradiated premedicated = 4.01 h).",Cystamine effect on the pharmacokinetics of imipramine in radiation sickness. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7395537/),h,4.01,161218,DB00458,Imipramine
,26149984,50% inhibitory concentrations (IC50s),"For P. falciparum, the median 50% inhibitory concentrations (IC50s) were 23.2 nM for PL69 and 26.6 nM for PL106, compared to 79.4 nM for unmodified CQ (P < 0.001 and P = 0.036, respectively).","Contrasting ex vivo efficacies of ""reversed chloroquine"" compounds in chloroquine-resistant Plasmodium falciparum and P. vivax isolates. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26149984/),nM,23.2,163952,DB00458,Imipramine
,26149984,50% inhibitory concentrations (IC50s),"For P. falciparum, the median 50% inhibitory concentrations (IC50s) were 23.2 nM for PL69 and 26.6 nM for PL106, compared to 79.4 nM for unmodified CQ (P < 0.001 and P = 0.036, respectively).","Contrasting ex vivo efficacies of ""reversed chloroquine"" compounds in chloroquine-resistant Plasmodium falciparum and P. vivax isolates. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26149984/),nM,26.6,163953,DB00458,Imipramine
,26149984,50% inhibitory concentrations (IC50s),"For P. falciparum, the median 50% inhibitory concentrations (IC50s) were 23.2 nM for PL69 and 26.6 nM for PL106, compared to 79.4 nM for unmodified CQ (P < 0.001 and P = 0.036, respectively).","Contrasting ex vivo efficacies of ""reversed chloroquine"" compounds in chloroquine-resistant Plasmodium falciparum and P. vivax isolates. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26149984/),nM,79.4,163954,DB00458,Imipramine
,26149984,IC50s,"Both RCQs were equally active against the ring and trophozoite stages of P. falciparum, but in P. vivax, PL69 and PL106 showed less potent activity against trophozoite stages (median IC50s, 130.2 and 172.5 nM) compared to ring stages (median IC50s, 17.6 and 91.3 nM).","Contrasting ex vivo efficacies of ""reversed chloroquine"" compounds in chloroquine-resistant Plasmodium falciparum and P. vivax isolates. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26149984/),nM,130.2,163955,DB00458,Imipramine
,26149984,IC50s,"Both RCQs were equally active against the ring and trophozoite stages of P. falciparum, but in P. vivax, PL69 and PL106 showed less potent activity against trophozoite stages (median IC50s, 130.2 and 172.5 nM) compared to ring stages (median IC50s, 17.6 and 91.3 nM).","Contrasting ex vivo efficacies of ""reversed chloroquine"" compounds in chloroquine-resistant Plasmodium falciparum and P. vivax isolates. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26149984/),nM,172.5,163956,DB00458,Imipramine
,26149984,IC50s,"Both RCQs were equally active against the ring and trophozoite stages of P. falciparum, but in P. vivax, PL69 and PL106 showed less potent activity against trophozoite stages (median IC50s, 130.2 and 172.5 nM) compared to ring stages (median IC50s, 17.6 and 91.3 nM).","Contrasting ex vivo efficacies of ""reversed chloroquine"" compounds in chloroquine-resistant Plasmodium falciparum and P. vivax isolates. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26149984/),nM,17.6,163957,DB00458,Imipramine
,26149984,IC50s,"Both RCQs were equally active against the ring and trophozoite stages of P. falciparum, but in P. vivax, PL69 and PL106 showed less potent activity against trophozoite stages (median IC50s, 130.2 and 172.5 nM) compared to ring stages (median IC50s, 17.6 and 91.3 nM).","Contrasting ex vivo efficacies of ""reversed chloroquine"" compounds in chloroquine-resistant Plasmodium falciparum and P. vivax isolates. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26149984/),nM,91.3,163958,DB00458,Imipramine
,29615471,Ki,"In the present study, we synthesized a series of novel 3-(benzo[d][1,3]dioxol-4-yloxy)-3-arylpropyl amine derivatives, among which compound H05 was identified as a lead, exhibiting potent inhibitory effects on both serotonin (Ki = 4.81 nM) and norepinephrine (NE) (Ki = 6.72 nM) transporters and moderate 5-HT2A antagonist activity (IC50 = 60.37 nM).","Pharmacological Characterization of H05, a Novel Serotonin and Noradrenaline Reuptake Inhibitor with Moderate 5-HT2A Antagonist Activity for the Treatment of Depression. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29615471/),nM,4.81,166369,DB00458,Imipramine
,29615471,Ki,"In the present study, we synthesized a series of novel 3-(benzo[d][1,3]dioxol-4-yloxy)-3-arylpropyl amine derivatives, among which compound H05 was identified as a lead, exhibiting potent inhibitory effects on both serotonin (Ki = 4.81 nM) and norepinephrine (NE) (Ki = 6.72 nM) transporters and moderate 5-HT2A antagonist activity (IC50 = 60.37 nM).","Pharmacological Characterization of H05, a Novel Serotonin and Noradrenaline Reuptake Inhibitor with Moderate 5-HT2A Antagonist Activity for the Treatment of Depression. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29615471/),nM,6.72,166370,DB00458,Imipramine
,29615471,IC50,"In the present study, we synthesized a series of novel 3-(benzo[d][1,3]dioxol-4-yloxy)-3-arylpropyl amine derivatives, among which compound H05 was identified as a lead, exhibiting potent inhibitory effects on both serotonin (Ki = 4.81 nM) and norepinephrine (NE) (Ki = 6.72 nM) transporters and moderate 5-HT2A antagonist activity (IC50 = 60.37 nM).","Pharmacological Characterization of H05, a Novel Serotonin and Noradrenaline Reuptake Inhibitor with Moderate 5-HT2A Antagonist Activity for the Treatment of Depression. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29615471/),nM,60.37,166371,DB00458,Imipramine
,1711447,elimination half-life,Its elimination half-life of 33 hours permits once daily oral administration.,"Citalopram. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness. ","t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1711447/),h,33,167736,DB00458,Imipramine
,4028632,t1/2,"There was no difference in the mean (+/- SE) t1/2 (9.0 +/- 0.8 vs. 10.9 +/- 1.6 hours), apparent volume of distribution (11.2 +/- 2.1 vs. 12.4 +/- 2.1 L/kg), or systemic clearance (992.2 +/- 138.3 vs. 930.3 +/- 101.9 ml/min/70 kg) of imipramine after dosing without and with oral activated charcoal, respectively (P greater than 0.05; paired t test).",Lack of effect of oral activated charcoal on imipramine clearance. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028632/),h,9.0,168188,DB00458,Imipramine
,4028632,t1/2,"There was no difference in the mean (+/- SE) t1/2 (9.0 +/- 0.8 vs. 10.9 +/- 1.6 hours), apparent volume of distribution (11.2 +/- 2.1 vs. 12.4 +/- 2.1 L/kg), or systemic clearance (992.2 +/- 138.3 vs. 930.3 +/- 101.9 ml/min/70 kg) of imipramine after dosing without and with oral activated charcoal, respectively (P greater than 0.05; paired t test).",Lack of effect of oral activated charcoal on imipramine clearance. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028632/),h,10.9,168189,DB00458,Imipramine
,4028632,apparent volume of distribution,"There was no difference in the mean (+/- SE) t1/2 (9.0 +/- 0.8 vs. 10.9 +/- 1.6 hours), apparent volume of distribution (11.2 +/- 2.1 vs. 12.4 +/- 2.1 L/kg), or systemic clearance (992.2 +/- 138.3 vs. 930.3 +/- 101.9 ml/min/70 kg) of imipramine after dosing without and with oral activated charcoal, respectively (P greater than 0.05; paired t test).",Lack of effect of oral activated charcoal on imipramine clearance. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028632/),[l] / [kg],11.2,168190,DB00458,Imipramine
,4028632,apparent volume of distribution,"There was no difference in the mean (+/- SE) t1/2 (9.0 +/- 0.8 vs. 10.9 +/- 1.6 hours), apparent volume of distribution (11.2 +/- 2.1 vs. 12.4 +/- 2.1 L/kg), or systemic clearance (992.2 +/- 138.3 vs. 930.3 +/- 101.9 ml/min/70 kg) of imipramine after dosing without and with oral activated charcoal, respectively (P greater than 0.05; paired t test).",Lack of effect of oral activated charcoal on imipramine clearance. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028632/),[l] / [kg],12.4,168191,DB00458,Imipramine
,4028632,systemic clearance,"There was no difference in the mean (+/- SE) t1/2 (9.0 +/- 0.8 vs. 10.9 +/- 1.6 hours), apparent volume of distribution (11.2 +/- 2.1 vs. 12.4 +/- 2.1 L/kg), or systemic clearance (992.2 +/- 138.3 vs. 930.3 +/- 101.9 ml/min/70 kg) of imipramine after dosing without and with oral activated charcoal, respectively (P greater than 0.05; paired t test).",Lack of effect of oral activated charcoal on imipramine clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028632/),[ml] / [70Â·kgÂ·min],992.2,168192,DB00458,Imipramine
,4028632,systemic clearance,"There was no difference in the mean (+/- SE) t1/2 (9.0 +/- 0.8 vs. 10.9 +/- 1.6 hours), apparent volume of distribution (11.2 +/- 2.1 vs. 12.4 +/- 2.1 L/kg), or systemic clearance (992.2 +/- 138.3 vs. 930.3 +/- 101.9 ml/min/70 kg) of imipramine after dosing without and with oral activated charcoal, respectively (P greater than 0.05; paired t test).",Lack of effect of oral activated charcoal on imipramine clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028632/),[ml] / [70Â·kgÂ·min],930.3,168193,DB00458,Imipramine
,6645788,adipose/,"Adipose/plasma and adipose/lung concentration ratios were 2-5 and 0.05, respectively.",Distribution of chlorpromazine and imipramine in adipose and other tissues of rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6645788/),,2,169917,DB00458,Imipramine
,6645788,adipose/,"Adipose/plasma and adipose/lung concentration ratios were 2-5 and 0.05, respectively.",Distribution of chlorpromazine and imipramine in adipose and other tissues of rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6645788/),,0.05,169918,DB00458,Imipramine
,14606931,oral bioavailability,"In an unselected population, oral bioavailability of tolterodine ranges from 10% to 74% (mean 33%) whereas in CYP2D6 extensive metabolisers and poor metabolisers mean bioavailabilities are 26% and 91%, respectively.",Clinical pharmacokinetics of drugs used to treat urge incontinence. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14606931/),%,10,171113,DB00458,Imipramine
,14606931,oral bioavailability,"In an unselected population, oral bioavailability of tolterodine ranges from 10% to 74% (mean 33%) whereas in CYP2D6 extensive metabolisers and poor metabolisers mean bioavailabilities are 26% and 91%, respectively.",Clinical pharmacokinetics of drugs used to treat urge incontinence. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14606931/),%,74,171114,DB00458,Imipramine
,14606931,oral bioavailability,"In an unselected population, oral bioavailability of tolterodine ranges from 10% to 74% (mean 33%) whereas in CYP2D6 extensive metabolisers and poor metabolisers mean bioavailabilities are 26% and 91%, respectively.",Clinical pharmacokinetics of drugs used to treat urge incontinence. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14606931/),%,33,171115,DB00458,Imipramine
,14606931,bioavailabilities,"In an unselected population, oral bioavailability of tolterodine ranges from 10% to 74% (mean 33%) whereas in CYP2D6 extensive metabolisers and poor metabolisers mean bioavailabilities are 26% and 91%, respectively.",Clinical pharmacokinetics of drugs used to treat urge incontinence. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14606931/),%,26,171116,DB00458,Imipramine
,14606931,bioavailabilities,"In an unselected population, oral bioavailability of tolterodine ranges from 10% to 74% (mean 33%) whereas in CYP2D6 extensive metabolisers and poor metabolisers mean bioavailabilities are 26% and 91%, respectively.",Clinical pharmacokinetics of drugs used to treat urge incontinence. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14606931/),%,91,171117,DB00458,Imipramine
,14606931,Terminal disposition half-lives,"Terminal disposition half-lives of tolterodine and 5-hydroxymethyl-tolterodine (in CYP2D6 extensive metabolisers) are 2-3 and 3-4 hours, respectively.",Clinical pharmacokinetics of drugs used to treat urge incontinence. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14606931/),h,2-3,171118,DB00458,Imipramine
,14606931,Terminal disposition half-lives,"Terminal disposition half-lives of tolterodine and 5-hydroxymethyl-tolterodine (in CYP2D6 extensive metabolisers) are 2-3 and 3-4 hours, respectively.",Clinical pharmacokinetics of drugs used to treat urge incontinence. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14606931/),h,3-4,171119,DB00458,Imipramine
,9088587,apparent oral clearance,"Ketoconazole administration was associated with a decrease in imipramine apparent oral clearance (from 1.16 +/- 0.21 to 0.96 +/- 0.20 l h-1 kg-1, mean +/- s.d.; P < 0.02), a prolongation in imipramine half-life (from 16.7 +/- 3.3 to 19.2 +/- 5.4 h, P < 0.05) and a decrease in area under the curve of metabolically derived desipramine (from 3507 +/- 1707 to 3180 +/- 1505 nmol l-1 h, P < 0.05), whereas concentrations of 2-hydroxy-imipramine were unaffected.",Effect of ketoconazole on the pharmacokinetics of imipramine and desipramine in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9088587/),[l] / [hÂ·kg],1.16,180537,DB00458,Imipramine
,9088587,apparent oral clearance,"Ketoconazole administration was associated with a decrease in imipramine apparent oral clearance (from 1.16 +/- 0.21 to 0.96 +/- 0.20 l h-1 kg-1, mean +/- s.d.; P < 0.02), a prolongation in imipramine half-life (from 16.7 +/- 3.3 to 19.2 +/- 5.4 h, P < 0.05) and a decrease in area under the curve of metabolically derived desipramine (from 3507 +/- 1707 to 3180 +/- 1505 nmol l-1 h, P < 0.05), whereas concentrations of 2-hydroxy-imipramine were unaffected.",Effect of ketoconazole on the pharmacokinetics of imipramine and desipramine in healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9088587/),[l] / [hÂ·kg],0.96,180538,DB00458,Imipramine
,9088587,half-life,"Ketoconazole administration was associated with a decrease in imipramine apparent oral clearance (from 1.16 +/- 0.21 to 0.96 +/- 0.20 l h-1 kg-1, mean +/- s.d.; P < 0.02), a prolongation in imipramine half-life (from 16.7 +/- 3.3 to 19.2 +/- 5.4 h, P < 0.05) and a decrease in area under the curve of metabolically derived desipramine (from 3507 +/- 1707 to 3180 +/- 1505 nmol l-1 h, P < 0.05), whereas concentrations of 2-hydroxy-imipramine were unaffected.",Effect of ketoconazole on the pharmacokinetics of imipramine and desipramine in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9088587/),h,16.7,180539,DB00458,Imipramine
,9088587,half-life,"Ketoconazole administration was associated with a decrease in imipramine apparent oral clearance (from 1.16 +/- 0.21 to 0.96 +/- 0.20 l h-1 kg-1, mean +/- s.d.; P < 0.02), a prolongation in imipramine half-life (from 16.7 +/- 3.3 to 19.2 +/- 5.4 h, P < 0.05) and a decrease in area under the curve of metabolically derived desipramine (from 3507 +/- 1707 to 3180 +/- 1505 nmol l-1 h, P < 0.05), whereas concentrations of 2-hydroxy-imipramine were unaffected.",Effect of ketoconazole on the pharmacokinetics of imipramine and desipramine in healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9088587/),h,19.2,180540,DB00458,Imipramine
,9088587,area under the curve,"Ketoconazole administration was associated with a decrease in imipramine apparent oral clearance (from 1.16 +/- 0.21 to 0.96 +/- 0.20 l h-1 kg-1, mean +/- s.d.; P < 0.02), a prolongation in imipramine half-life (from 16.7 +/- 3.3 to 19.2 +/- 5.4 h, P < 0.05) and a decrease in area under the curve of metabolically derived desipramine (from 3507 +/- 1707 to 3180 +/- 1505 nmol l-1 h, P < 0.05), whereas concentrations of 2-hydroxy-imipramine were unaffected.",Effect of ketoconazole on the pharmacokinetics of imipramine and desipramine in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9088587/),[hÂ·nM] / [l],3507,180541,DB00458,Imipramine
,9088587,area under the curve,"Ketoconazole administration was associated with a decrease in imipramine apparent oral clearance (from 1.16 +/- 0.21 to 0.96 +/- 0.20 l h-1 kg-1, mean +/- s.d.; P < 0.02), a prolongation in imipramine half-life (from 16.7 +/- 3.3 to 19.2 +/- 5.4 h, P < 0.05) and a decrease in area under the curve of metabolically derived desipramine (from 3507 +/- 1707 to 3180 +/- 1505 nmol l-1 h, P < 0.05), whereas concentrations of 2-hydroxy-imipramine were unaffected.",Effect of ketoconazole on the pharmacokinetics of imipramine and desipramine in healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9088587/),[hÂ·nM] / [l],3180,180542,DB00458,Imipramine
,6775331,apparent elimination half-life,"The apparent elimination half-life of imipramine was 20.8-34.9h (means 26.4h), its biovailability (F) was 40-64% (means 57%), and the apparent plasma clearance was from 0.27-0.57h/kg (mean 0.41h/kg).",Comparison of single-dose pharmacokinetics of imipramine and maprotiline in the elderly. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6775331/),h,20.8-34.9,182825,DB00458,Imipramine
,6775331,apparent elimination half-life,"The apparent elimination half-life of imipramine was 20.8-34.9h (means 26.4h), its biovailability (F) was 40-64% (means 57%), and the apparent plasma clearance was from 0.27-0.57h/kg (mean 0.41h/kg).",Comparison of single-dose pharmacokinetics of imipramine and maprotiline in the elderly. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6775331/),h,26.4,182826,DB00458,Imipramine
,6775331,biovailability (F),"The apparent elimination half-life of imipramine was 20.8-34.9h (means 26.4h), its biovailability (F) was 40-64% (means 57%), and the apparent plasma clearance was from 0.27-0.57h/kg (mean 0.41h/kg).",Comparison of single-dose pharmacokinetics of imipramine and maprotiline in the elderly. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6775331/),%,40-64,182827,DB00458,Imipramine
,6775331,biovailability (F),"The apparent elimination half-life of imipramine was 20.8-34.9h (means 26.4h), its biovailability (F) was 40-64% (means 57%), and the apparent plasma clearance was from 0.27-0.57h/kg (mean 0.41h/kg).",Comparison of single-dose pharmacokinetics of imipramine and maprotiline in the elderly. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6775331/),%,57,182828,DB00458,Imipramine
,6775331,apparent plasma clearance,"The apparent elimination half-life of imipramine was 20.8-34.9h (means 26.4h), its biovailability (F) was 40-64% (means 57%), and the apparent plasma clearance was from 0.27-0.57h/kg (mean 0.41h/kg).",Comparison of single-dose pharmacokinetics of imipramine and maprotiline in the elderly. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6775331/),[h] / [kg],0.41,182829,DB00458,Imipramine
,6775331,half-life,"Maprotiline had a longer half-life (mean 31.5h range 20.6-51.8h, but its bioavailability (mean 50%) and plasma clearance (mean 0.49h/kg) values were in the range similar to those seen after imipramine.",Comparison of single-dose pharmacokinetics of imipramine and maprotiline in the elderly. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6775331/),h,31.5,182830,DB00458,Imipramine
,6775331,bioavailability,"Maprotiline had a longer half-life (mean 31.5h range 20.6-51.8h, but its bioavailability (mean 50%) and plasma clearance (mean 0.49h/kg) values were in the range similar to those seen after imipramine.",Comparison of single-dose pharmacokinetics of imipramine and maprotiline in the elderly. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6775331/),%,50,182831,DB00458,Imipramine
,6775331,plasma clearance,"Maprotiline had a longer half-life (mean 31.5h range 20.6-51.8h, but its bioavailability (mean 50%) and plasma clearance (mean 0.49h/kg) values were in the range similar to those seen after imipramine.",Comparison of single-dose pharmacokinetics of imipramine and maprotiline in the elderly. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6775331/),[h] / [kg],0.49,182832,DB00458,Imipramine
,26686828,relative recoveries,The method was validated over a concentration range of 0.1-100ng/mL for all the three analytes with relative recoveries ranging from 69 to 82%.,"A high throughput flow gradient LC-MS/MS method for simultaneous determination of fingolimod, fampridine and prednisone in rat plasma, application to in vivo perfusion study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26686828/),%,69 to 82,183278,DB00458,Imipramine
,16213473,K(D),Occupation of 5-HTT sites saturates at low plasma sertraline levels (K(D) = 1.9 ng/ml) with maximal occupancies of 106.8 +/- 8.3% across all brain regions.,Acute occupancy of brain serotonin transporter by sertraline as measured by [11C]DASB and positron emission tomography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16213473/),[ng] / [ml],1.9,188042,DB00458,Imipramine
,16213473,maximal occupancies,Occupation of 5-HTT sites saturates at low plasma sertraline levels (K(D) = 1.9 ng/ml) with maximal occupancies of 106.8 +/- 8.3% across all brain regions.,Acute occupancy of brain serotonin transporter by sertraline as measured by [11C]DASB and positron emission tomography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16213473/),%,106.8,188043,DB00458,Imipramine
above,2185906,steady-state plasma concentrations,"In at least a third of the population, nonlinear pharmacokinetics of desipramine may be observed at steady-state plasma concentrations above 150 micrograms/L.",Clinical pharmacokinetics of imipramine and desipramine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2185906/),[Î¼g] / [l],150,190551,DB00458,Imipramine
,23100243,recovery,"The average recovery was 90.1 and 98.4% from rat plasma for KR-62980 and imipramine, respectively.",LC-MS-based method for the qualitative and quantitative analysis of the novel PPARÎ³ agonist KR-62980. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23100243/),%,90.1,190556,DB00458,Imipramine
,23100243,recovery,"The average recovery was 90.1 and 98.4% from rat plasma for KR-62980 and imipramine, respectively.",LC-MS-based method for the qualitative and quantitative analysis of the novel PPARÎ³ agonist KR-62980. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23100243/),%,98.4,190557,DB00458,Imipramine
,3365915,total body clearance,Alcoholics had significantly greater total body clearance of imipramine (0.93 vs. 0.48 L/hr/kg; P less than 0.05) and desipramine (1.00 vs. 0.62 L/hr/kg; P less than 0.05) than did control subjects.,Clinical pharmacokinetics of imipramine and desipramine in alcoholics and normal volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3365915/),[l] / [hÂ·kg],0.93,191305,DB00458,Imipramine
,3365915,total body clearance,Alcoholics had significantly greater total body clearance of imipramine (0.93 vs. 0.48 L/hr/kg; P less than 0.05) and desipramine (1.00 vs. 0.62 L/hr/kg; P less than 0.05) than did control subjects.,Clinical pharmacokinetics of imipramine and desipramine in alcoholics and normal volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3365915/),[l] / [hÂ·kg],0.48,191306,DB00458,Imipramine
,3365915,total body clearance,Alcoholics had significantly greater total body clearance of imipramine (0.93 vs. 0.48 L/hr/kg; P less than 0.05) and desipramine (1.00 vs. 0.62 L/hr/kg; P less than 0.05) than did control subjects.,Clinical pharmacokinetics of imipramine and desipramine in alcoholics and normal volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3365915/),[l] / [hÂ·kg],1.00,191307,DB00458,Imipramine
,3365915,total body clearance,Alcoholics had significantly greater total body clearance of imipramine (0.93 vs. 0.48 L/hr/kg; P less than 0.05) and desipramine (1.00 vs. 0.62 L/hr/kg; P less than 0.05) than did control subjects.,Clinical pharmacokinetics of imipramine and desipramine in alcoholics and normal volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3365915/),[l] / [hÂ·kg],0.62,191308,DB00458,Imipramine
,3365915,Intrinsic clearance,"Intrinsic clearance of unbound imipramine was greater in the alcoholic group (19.80 vs. 6.56 L/hr/kg; P less than 0.05), as was the intrinsic clearance of unbound desipramine (14.52 vs. 9.05 L/hr/kg; P less than 0.05).",Clinical pharmacokinetics of imipramine and desipramine in alcoholics and normal volunteers. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3365915/),[l] / [hÂ·kg],19.80,191309,DB00458,Imipramine
,3365915,Intrinsic clearance,"Intrinsic clearance of unbound imipramine was greater in the alcoholic group (19.80 vs. 6.56 L/hr/kg; P less than 0.05), as was the intrinsic clearance of unbound desipramine (14.52 vs. 9.05 L/hr/kg; P less than 0.05).",Clinical pharmacokinetics of imipramine and desipramine in alcoholics and normal volunteers. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3365915/),[l] / [hÂ·kg],6.56,191310,DB00458,Imipramine
,3365915,intrinsic clearance of unbound desipramine,"Intrinsic clearance of unbound imipramine was greater in the alcoholic group (19.80 vs. 6.56 L/hr/kg; P less than 0.05), as was the intrinsic clearance of unbound desipramine (14.52 vs. 9.05 L/hr/kg; P less than 0.05).",Clinical pharmacokinetics of imipramine and desipramine in alcoholics and normal volunteers. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3365915/),[l] / [hÂ·kg],14.52,191311,DB00458,Imipramine
,3365915,intrinsic clearance of unbound desipramine,"Intrinsic clearance of unbound imipramine was greater in the alcoholic group (19.80 vs. 6.56 L/hr/kg; P less than 0.05), as was the intrinsic clearance of unbound desipramine (14.52 vs. 9.05 L/hr/kg; P less than 0.05).",Clinical pharmacokinetics of imipramine and desipramine in alcoholics and normal volunteers. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3365915/),[l] / [hÂ·kg],9.05,191312,DB00458,Imipramine
,3365915,elimination half-life,The mean elimination half-life for imipramine was significantly decreased in alcoholics (8.7 vs.,Clinical pharmacokinetics of imipramine and desipramine in alcoholics and normal volunteers. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3365915/),,8.7,191313,DB00458,Imipramine
,3365915,elimination half-life,The mean elimination half-life for desipramine was decreased in alcoholics after intravenous infusion (16.5 vs. 22.4 hours; P less than 0.05).,Clinical pharmacokinetics of imipramine and desipramine in alcoholics and normal volunteers. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3365915/),h,16.5,191314,DB00458,Imipramine
,3365915,elimination half-life,The mean elimination half-life for desipramine was decreased in alcoholics after intravenous infusion (16.5 vs. 22.4 hours; P less than 0.05).,Clinical pharmacokinetics of imipramine and desipramine in alcoholics and normal volunteers. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3365915/),h,22.4,191315,DB00458,Imipramine
,32879225,activation energy (Ea),The degradation was a pseudo first-order reaction; activation energy (Ea) was 88.70 kJ/mol and activation entropy (ÎS) was -80.73 J/KÂ·mol.,Elucidation of Degradation Behavior of Tricyclic Antidepressant Amoxapine in Artificial Gastric Juice. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32879225/),[kj] / [mol],88.70,195214,DB00458,Imipramine
,32879225,activation entropy (ÎS),The degradation was a pseudo first-order reaction; activation energy (Ea) was 88.70 kJ/mol and activation entropy (ÎS) was -80.73 J/KÂ·mol.,Elucidation of Degradation Behavior of Tricyclic Antidepressant Amoxapine in Artificial Gastric Juice. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32879225/),[j] / [kÂ·mol],-,195215,DB00458,Imipramine
,32879225,activation entropy (ÎS),The degradation was a pseudo first-order reaction; activation energy (Ea) was 88.70 kJ/mol and activation entropy (ÎS) was -80.73 J/KÂ·mol.,Elucidation of Degradation Behavior of Tricyclic Antidepressant Amoxapine in Artificial Gastric Juice. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32879225/),[j] / [kÂ·mol],80.73,195216,DB00458,Imipramine
,32879225,retention times,"In the AMX degradation experiment, peaks considered to be degradation products A (I) and B (II) were detected at retention times of around 3 min and 30 min in LC/UV measurements, respectively.",Elucidation of Degradation Behavior of Tricyclic Antidepressant Amoxapine in Artificial Gastric Juice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32879225/),min,3,195217,DB00458,Imipramine
,32879225,retention times,"In the AMX degradation experiment, peaks considered to be degradation products A (I) and B (II) were detected at retention times of around 3 min and 30 min in LC/UV measurements, respectively.",Elucidation of Degradation Behavior of Tricyclic Antidepressant Amoxapine in Artificial Gastric Juice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32879225/),min,30,195218,DB00458,Imipramine
,8803904,bioavailability,Hydroxychloroquine (HCQ) and chloroquine (CQ) are well absorbed (0.7-0.8 bioavailability) when given orally.,Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8803904/),,0.7-0.8,195382,DB00458,Imipramine
,8803904,half-lives,"Both HCQ and CQ have prolonged half-lives, between 40 and 50 days, and low blood clearance (e.g. hydroxychloroquine's blood clearance is 96 ml/min).",Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8803904/),d,40 and 50,195383,DB00458,Imipramine
,8803904,blood clearance,"Both HCQ and CQ have prolonged half-lives, between 40 and 50 days, and low blood clearance (e.g. hydroxychloroquine's blood clearance is 96 ml/min).",Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8803904/),[ml] / [min],96,195384,DB00458,Imipramine
,8803904,Protein binding,"Protein binding ranges between 30 and 40% with binding to both albumin and alpha, glycoprotein.",Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8803904/),%,30 and 40,195385,DB00458,Imipramine
,1126113,systemic availability,The systemic availability of orally administered imipramine (IP) varied from 29 to 77% in 4 subjects.,First-pass metabolism of imipramine in man. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1126113/),%,29 to 77,195752,DB00458,Imipramine
,25558834,Chb,"Values for Cb s corresponded to the actual values for all tested drugs, and mean Chb and maximal Chb -to-maximal Cb ratio predicted for oral fluvoxamine administration (50 mg twice-a-day administration) were nearly 100 nM and 2.3, respectively, which would be useful for the predictions of the DDIs caused by fluvoxamine.",Use of three-compartment physiologically based pharmacokinetic modeling to predict hepatic blood levels of fluvoxamine relevant for drug-drug interactions. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25558834/),nM,100,195960,DB00458,Imipramine
,25558834,maximal Chb -to-maximal Cb ratio,"Values for Cb s corresponded to the actual values for all tested drugs, and mean Chb and maximal Chb -to-maximal Cb ratio predicted for oral fluvoxamine administration (50 mg twice-a-day administration) were nearly 100 nM and 2.3, respectively, which would be useful for the predictions of the DDIs caused by fluvoxamine.",Use of three-compartment physiologically based pharmacokinetic modeling to predict hepatic blood levels of fluvoxamine relevant for drug-drug interactions. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25558834/),,2.3,195961,DB00458,Imipramine
,25558834,liver uptake,"Fluvoxamine and tacrine are known to exhibit relatively large F values despite having CLtot similar to or larger than hepatic blood flow, which may be because of the high liver uptake (almost 0.6) upon intravenous administration.",Use of three-compartment physiologically based pharmacokinetic modeling to predict hepatic blood levels of fluvoxamine relevant for drug-drug interactions. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25558834/),,0.6,195962,DB00458,Imipramine
,6466342,Biliary excretion,Biliary excretion of imipramine metabolites was 79.3% of the dose in control rats.,The prevention by (+)-Cyanidanol-3 of hepatitis-induced changes in the disposition of imipramine in the rat. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6466342/),%,79,198503,DB00458,Imipramine
,31222787,flow rate,"Mequitazine was separated by UPLC-MS/MS equipped with a Kinetex core-shell C18 column (50 Ã 2.1 mm, 1.7 Î¼m) using 0.1% (v/v) aqueous formic acid and acetonitrile containing 0.1% (v/v) formic acid as a mobile phase by gradient elution at a flow rate of 0.3 mL/min.",A novel and sensitive UPLC-MS/MS method to determine mequitazine in rat plasma and urine: Validation and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31222787/),[ml] / [min],0.3,206546,DB00458,Imipramine
,31222787,Mass transitions,Mass transitions were m/z 323.3 â 83.1 for mequitazine and 281.3 â 86.3 for imipramine as internal standard.,A novel and sensitive UPLC-MS/MS method to determine mequitazine in rat plasma and urine: Validation and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31222787/),,323.3,206547,DB00458,Imipramine
,31222787,Mass transitions,Mass transitions were m/z 323.3 â 83.1 for mequitazine and 281.3 â 86.3 for imipramine as internal standard.,A novel and sensitive UPLC-MS/MS method to determine mequitazine in rat plasma and urine: Validation and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31222787/),,281.3,206548,DB00458,Imipramine
,31222787,m/z,Mass transitions were m/z 323.3 â 83.1 for mequitazine and 281.3 â 86.3 for imipramine as internal standard.,A novel and sensitive UPLC-MS/MS method to determine mequitazine in rat plasma and urine: Validation and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31222787/),,323.3,206549,DB00458,Imipramine
,31222787,m/z,Mass transitions were m/z 323.3 â 83.1 for mequitazine and 281.3 â 86.3 for imipramine as internal standard.,A novel and sensitive UPLC-MS/MS method to determine mequitazine in rat plasma and urine: Validation and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31222787/),,83.1,206550,DB00458,Imipramine
,31222787,m/z,Mass transitions were m/z 323.3 â 83.1 for mequitazine and 281.3 â 86.3 for imipramine as internal standard.,A novel and sensitive UPLC-MS/MS method to determine mequitazine in rat plasma and urine: Validation and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31222787/),,281.3,206551,DB00458,Imipramine
,31222787,m/z,Mass transitions were m/z 323.3 â 83.1 for mequitazine and 281.3 â 86.3 for imipramine as internal standard.,A novel and sensitive UPLC-MS/MS method to determine mequitazine in rat plasma and urine: Validation and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31222787/),,86.3,206552,DB00458,Imipramine
,6726654,elimination half-life,"After i.v. doses, elimination half-life of imipramine was increased during cimetidine treatment (22.1 vs. 15.5 hr, P less than .02) as a result of decreased total metabolic clearance (623 vs. 1048 ml/min, P less than .05) with no change in volume of distribution (17.2 vs. 19.8 liters/kg) or plasma protein binding (unbound percent, 17.7 vs. 16.5%).",Imipramine-cimetidine interaction: impairment of clearance and enhanced absolute bioavailability. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6726654/),h,22.1,206980,DB00458,Imipramine
,6726654,elimination half-life,"After i.v. doses, elimination half-life of imipramine was increased during cimetidine treatment (22.1 vs. 15.5 hr, P less than .02) as a result of decreased total metabolic clearance (623 vs. 1048 ml/min, P less than .05) with no change in volume of distribution (17.2 vs. 19.8 liters/kg) or plasma protein binding (unbound percent, 17.7 vs. 16.5%).",Imipramine-cimetidine interaction: impairment of clearance and enhanced absolute bioavailability. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6726654/),h,15.5,206981,DB00458,Imipramine
,6726654,total metabolic clearance,"After i.v. doses, elimination half-life of imipramine was increased during cimetidine treatment (22.1 vs. 15.5 hr, P less than .02) as a result of decreased total metabolic clearance (623 vs. 1048 ml/min, P less than .05) with no change in volume of distribution (17.2 vs. 19.8 liters/kg) or plasma protein binding (unbound percent, 17.7 vs. 16.5%).",Imipramine-cimetidine interaction: impairment of clearance and enhanced absolute bioavailability. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6726654/),[ml] / [min],623,206982,DB00458,Imipramine
,6726654,total metabolic clearance,"After i.v. doses, elimination half-life of imipramine was increased during cimetidine treatment (22.1 vs. 15.5 hr, P less than .02) as a result of decreased total metabolic clearance (623 vs. 1048 ml/min, P less than .05) with no change in volume of distribution (17.2 vs. 19.8 liters/kg) or plasma protein binding (unbound percent, 17.7 vs. 16.5%).",Imipramine-cimetidine interaction: impairment of clearance and enhanced absolute bioavailability. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6726654/),[ml] / [min],1048,206983,DB00458,Imipramine
,6726654,volume of distribution,"After i.v. doses, elimination half-life of imipramine was increased during cimetidine treatment (22.1 vs. 15.5 hr, P less than .02) as a result of decreased total metabolic clearance (623 vs. 1048 ml/min, P less than .05) with no change in volume of distribution (17.2 vs. 19.8 liters/kg) or plasma protein binding (unbound percent, 17.7 vs. 16.5%).",Imipramine-cimetidine interaction: impairment of clearance and enhanced absolute bioavailability. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6726654/),[l] / [kg],17.2,206984,DB00458,Imipramine
,6726654,volume of distribution,"After i.v. doses, elimination half-life of imipramine was increased during cimetidine treatment (22.1 vs. 15.5 hr, P less than .02) as a result of decreased total metabolic clearance (623 vs. 1048 ml/min, P less than .05) with no change in volume of distribution (17.2 vs. 19.8 liters/kg) or plasma protein binding (unbound percent, 17.7 vs. 16.5%).",Imipramine-cimetidine interaction: impairment of clearance and enhanced absolute bioavailability. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6726654/),[l] / [kg],19.8,206985,DB00458,Imipramine
,6726654,unbound percent,"After i.v. doses, elimination half-life of imipramine was increased during cimetidine treatment (22.1 vs. 15.5 hr, P less than .02) as a result of decreased total metabolic clearance (623 vs. 1048 ml/min, P less than .05) with no change in volume of distribution (17.2 vs. 19.8 liters/kg) or plasma protein binding (unbound percent, 17.7 vs. 16.5%).",Imipramine-cimetidine interaction: impairment of clearance and enhanced absolute bioavailability. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6726654/),%,17.7,206986,DB00458,Imipramine
,6726654,unbound percent,"After i.v. doses, elimination half-life of imipramine was increased during cimetidine treatment (22.1 vs. 15.5 hr, P less than .02) as a result of decreased total metabolic clearance (623 vs. 1048 ml/min, P less than .05) with no change in volume of distribution (17.2 vs. 19.8 liters/kg) or plasma protein binding (unbound percent, 17.7 vs. 16.5%).",Imipramine-cimetidine interaction: impairment of clearance and enhanced absolute bioavailability. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6726654/),%,16.5,206987,DB00458,Imipramine
,6726654,peak imipramine blood levels,"After single p.o. imipramine doses, peak imipramine blood levels achieved were greater during cimetidine therapy (34.4 vs. 19.3 ng/ml, P less than .05) and area under the time/concentration curve was greatly increased (569 vs. 306 ng/ml X hr, P less than .05).",Imipramine-cimetidine interaction: impairment of clearance and enhanced absolute bioavailability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6726654/),[ng] / [ml],34.4,206988,DB00458,Imipramine
,6726654,peak imipramine blood levels,"After single p.o. imipramine doses, peak imipramine blood levels achieved were greater during cimetidine therapy (34.4 vs. 19.3 ng/ml, P less than .05) and area under the time/concentration curve was greatly increased (569 vs. 306 ng/ml X hr, P less than .05).",Imipramine-cimetidine interaction: impairment of clearance and enhanced absolute bioavailability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6726654/),[ng] / [ml],19.3,206989,DB00458,Imipramine
,6726654,area under the time/concentration curve,"After single p.o. imipramine doses, peak imipramine blood levels achieved were greater during cimetidine therapy (34.4 vs. 19.3 ng/ml, P less than .05) and area under the time/concentration curve was greatly increased (569 vs. 306 ng/ml X hr, P less than .05).",Imipramine-cimetidine interaction: impairment of clearance and enhanced absolute bioavailability. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6726654/),[ng] / [hÂ·ml],569,206990,DB00458,Imipramine
,6726654,area under the time/concentration curve,"After single p.o. imipramine doses, peak imipramine blood levels achieved were greater during cimetidine therapy (34.4 vs. 19.3 ng/ml, P less than .05) and area under the time/concentration curve was greatly increased (569 vs. 306 ng/ml X hr, P less than .05).",Imipramine-cimetidine interaction: impairment of clearance and enhanced absolute bioavailability. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6726654/),[ng] / [hÂ·ml],306,206991,DB00458,Imipramine
,6726654,area under the time/concentration curve,"Desipramine area under the time/concentration curve was increased during cimetidine therapy after p.o. imipramine doses (274 vs. 152 ng/ml X hr, P less than .05), suggesting that desipramine clearance was inhibited as well.",Imipramine-cimetidine interaction: impairment of clearance and enhanced absolute bioavailability. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6726654/),[ng] / [hÂ·ml],274,206992,DB00458,Imipramine
,6726654,area under the time/concentration curve,"Desipramine area under the time/concentration curve was increased during cimetidine therapy after p.o. imipramine doses (274 vs. 152 ng/ml X hr, P less than .05), suggesting that desipramine clearance was inhibited as well.",Imipramine-cimetidine interaction: impairment of clearance and enhanced absolute bioavailability. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6726654/),[ng] / [hÂ·ml],152,206993,DB00458,Imipramine
,6726654,absolute bioavailability,Comparison of i.v. and p.o. imipramine doses indicated absolute bioavailability was 40.2% in the control state and increased to 75.3% (P less than .05) during cimetidine treatment.,Imipramine-cimetidine interaction: impairment of clearance and enhanced absolute bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6726654/),%,40.2,206994,DB00458,Imipramine
,6726654,absolute bioavailability,Comparison of i.v. and p.o. imipramine doses indicated absolute bioavailability was 40.2% in the control state and increased to 75.3% (P less than .05) during cimetidine treatment.,Imipramine-cimetidine interaction: impairment of clearance and enhanced absolute bioavailability. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6726654/),%,75.3,206995,DB00458,Imipramine
,15212193,limit of detection,The limit of detection was 6 ng/ml.,Bioavailability study of drotaverine from capsule and tablet preparations in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15212193/),[ng] / [ml],6,210142,DB00458,Imipramine
,15212193,AUC(0-infinity),Values of 1593.92 +/- 949.70 ng x h/l (95% confidence interval (CI): 1183.20-2004.60) for the test and 1705.48 +/- 737.78 ng x h/l (95% CI: 1386.40-2024.50) for the reference preparation AUC(0-infinity) demonstrate a nearly identical extent of drug absorption.,Bioavailability study of drotaverine from capsule and tablet preparations in healthy volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15212193/),[hÂ·ng] / [l],1705.48,210143,DB00458,Imipramine
,15212193,Maximum concentrations--Cmax,Maximum concentrations--Cmax of 121.89 +/- 37.03 ng/ml (95% CI: 104.05-139.80) and 121.85 +/- 37.97 ng/ml (95% CI: 107.09-135.74) and time to reach maximum plasma concentration--Tmax of 1.29 +/- 0.42 h (95% CI: 1.11-1.48) and 1.14 +/- 0.34 h (95% CI: 0.99-1.29) achieved for the test and reference preparations did not differ significantly.,Bioavailability study of drotaverine from capsule and tablet preparations in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15212193/),[ng] / [ml],121.89,210144,DB00458,Imipramine
,15212193,Maximum concentrations--Cmax,Maximum concentrations--Cmax of 121.89 +/- 37.03 ng/ml (95% CI: 104.05-139.80) and 121.85 +/- 37.97 ng/ml (95% CI: 107.09-135.74) and time to reach maximum plasma concentration--Tmax of 1.29 +/- 0.42 h (95% CI: 1.11-1.48) and 1.14 +/- 0.34 h (95% CI: 0.99-1.29) achieved for the test and reference preparations did not differ significantly.,Bioavailability study of drotaverine from capsule and tablet preparations in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15212193/),[ng] / [ml],121.85,210145,DB00458,Imipramine
,15212193,time to reach maximum plasma concentration--Tmax,Maximum concentrations--Cmax of 121.89 +/- 37.03 ng/ml (95% CI: 104.05-139.80) and 121.85 +/- 37.97 ng/ml (95% CI: 107.09-135.74) and time to reach maximum plasma concentration--Tmax of 1.29 +/- 0.42 h (95% CI: 1.11-1.48) and 1.14 +/- 0.34 h (95% CI: 0.99-1.29) achieved for the test and reference preparations did not differ significantly.,Bioavailability study of drotaverine from capsule and tablet preparations in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15212193/),h,1.29,210146,DB00458,Imipramine
,15212193,time to reach maximum plasma concentration--Tmax,Maximum concentrations--Cmax of 121.89 +/- 37.03 ng/ml (95% CI: 104.05-139.80) and 121.85 +/- 37.97 ng/ml (95% CI: 107.09-135.74) and time to reach maximum plasma concentration--Tmax of 1.29 +/- 0.42 h (95% CI: 1.11-1.48) and 1.14 +/- 0.34 h (95% CI: 0.99-1.29) achieved for the test and reference preparations did not differ significantly.,Bioavailability study of drotaverine from capsule and tablet preparations in healthy volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15212193/),h,1.14,210147,DB00458,Imipramine
,15212193,relative bioavailability (AUC(0-infinity) ratio,"The relative bioavailability (AUC(0-infinity) ratio test/reference) and Cmax ratio test/reference were 103.15% (90% CI: 81.68-124.60) and 103.74% (90% CI: 94.10-113.38), respectively.",Bioavailability study of drotaverine from capsule and tablet preparations in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15212193/),%,103.15,210148,DB00458,Imipramine
,15212193,relative bioavailability (AUC(0-infinity) ratio,"The relative bioavailability (AUC(0-infinity) ratio test/reference) and Cmax ratio test/reference were 103.15% (90% CI: 81.68-124.60) and 103.74% (90% CI: 94.10-113.38), respectively.",Bioavailability study of drotaverine from capsule and tablet preparations in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15212193/),%,103.74,210149,DB00458,Imipramine
,29079874,t 1/2,Pharmacokinetic in vivo investigation showed a rapid absorption of EMD386088 (2.5 and 5 mg/kg) with t 1/2 = 67 min (t max = 5 min).,"Study on the effect of EMD386088, a 5-HT6 receptor partial agonist, in enhancing the anti-immobility action of some antidepressants in rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29079874/),min,67,216604,DB00458,Imipramine
,29079874,t max,Pharmacokinetic in vivo investigation showed a rapid absorption of EMD386088 (2.5 and 5 mg/kg) with t 1/2 = 67 min (t max = 5 min).,"Study on the effect of EMD386088, a 5-HT6 receptor partial agonist, in enhancing the anti-immobility action of some antidepressants in rats. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29079874/),min,5,216605,DB00458,Imipramine
,29079874,volume of distribution (V d/F,Large volume of distribution (V d/F = 102 L/kg) indicated its penetration into peripheral compartments.,"Study on the effect of EMD386088, a 5-HT6 receptor partial agonist, in enhancing the anti-immobility action of some antidepressants in rats. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29079874/),[l] / [kg],102,216606,DB00458,Imipramine
,29079874,C max,The most active coadministration of EMD386088 (2.5 mg/kg) with imipramine (15 mg/kg) resulted in slower absorption of the compound (C max = 60 min) and decrease in the volume of distribution (V d/F = 32.2 L/kg).,"Study on the effect of EMD386088, a 5-HT6 receptor partial agonist, in enhancing the anti-immobility action of some antidepressants in rats. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29079874/),min,60,216607,DB00458,Imipramine
,29079874,volume of distribution (V d/F,The most active coadministration of EMD386088 (2.5 mg/kg) with imipramine (15 mg/kg) resulted in slower absorption of the compound (C max = 60 min) and decrease in the volume of distribution (V d/F = 32.2 L/kg).,"Study on the effect of EMD386088, a 5-HT6 receptor partial agonist, in enhancing the anti-immobility action of some antidepressants in rats. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29079874/),[l] / [kg],32.2,216608,DB00458,Imipramine
,29079874,brain/plasma ratio,EMD386088 penetrates the blood-brain barrier with a high brain/plasma ratio of about 19 (2.5 mg/kg) and 7.5 for coadministration with imipramine.,"Study on the effect of EMD386088, a 5-HT6 receptor partial agonist, in enhancing the anti-immobility action of some antidepressants in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29079874/),,19,216609,DB00458,Imipramine
,29079874,brain/plasma ratio,EMD386088 penetrates the blood-brain barrier with a high brain/plasma ratio of about 19 (2.5 mg/kg) and 7.5 for coadministration with imipramine.,"Study on the effect of EMD386088, a 5-HT6 receptor partial agonist, in enhancing the anti-immobility action of some antidepressants in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29079874/),,7.5,216610,DB00458,Imipramine
,29079874,IC 50,"EMD386088 did not influence on CYP3A4 activity, and it has been classified as a very weak CYP2D6 inhibitor (IC 50 = 2.25 Î¼M).","Study on the effect of EMD386088, a 5-HT6 receptor partial agonist, in enhancing the anti-immobility action of some antidepressants in rats. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29079874/),Î¼M,2.25,216611,DB00458,Imipramine
,28911626,relative recoveries,"The method was validated over a concentration range of 0.1-100 ng/mL for all the three analytes, with relative recoveries ranging from 69% to 82%.","High-throughput liquid chromatography tandem mass spectrometry method for simultaneous determination of fampridine, paroxetine, and quinidine in rat plasma: Application to in vivo perfusion study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28911626/),%,69,217913,DB00458,Imipramine
,28911626,relative recoveries,"The method was validated over a concentration range of 0.1-100 ng/mL for all the three analytes, with relative recoveries ranging from 69% to 82%.","High-throughput liquid chromatography tandem mass spectrometry method for simultaneous determination of fampridine, paroxetine, and quinidine in rat plasma: Application to in vivo perfusion study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28911626/),%,82,217914,DB00458,Imipramine
,1544284,oral clearance,"Desipramine oral clearance values were 289, 112, and 27 L/hr alone, after a single fluoxetine dose, and after multiple fluoxetine doses, respectively.",Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1544284/),[l] / [h],289,219612,DB00458,Imipramine
,1544284,oral clearance,"Desipramine oral clearance values were 289, 112, and 27 L/hr alone, after a single fluoxetine dose, and after multiple fluoxetine doses, respectively.",Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1544284/),[l] / [h],112,219613,DB00458,Imipramine
,1544284,oral clearance,"Desipramine oral clearance values were 289, 112, and 27 L/hr alone, after a single fluoxetine dose, and after multiple fluoxetine doses, respectively.",Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1544284/),[l] / [h],27,219614,DB00458,Imipramine
,1544284,oral clearance,"Correspondingly, imipramine oral clearance values were 181, 87, and 51 L/hr.",Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1544284/),[l] / [h],181,219615,DB00458,Imipramine
,1544284,oral clearance,"Correspondingly, imipramine oral clearance values were 181, 87, and 51 L/hr.",Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1544284/),[l] / [h],87,219616,DB00458,Imipramine
,1544284,oral clearance,"Correspondingly, imipramine oral clearance values were 181, 87, and 51 L/hr.",Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1544284/),[l] / [h],51,219617,DB00458,Imipramine
,1794155,maximal brain concentrations (Cmax),"After single i.p. application of IMI, maximal brain concentrations (Cmax) of IMI and DMI were nearly twofold higher in darkness (IMI, 4.8 micrograms/g; DMI, 1.8 micrograms/g) than in light (IMI, 2.85 micrograms/g; DMI, 0.85 microgram/g).",Chronopharmacokinetics of imipramine and desipramine in rat forebrain and plasma after single and chronic treatment with imipramine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1794155/),[Î¼g] / [g],4.8,222764,DB00458,Imipramine
,1794155,maximal brain concentrations (Cmax),"After single i.p. application of IMI, maximal brain concentrations (Cmax) of IMI and DMI were nearly twofold higher in darkness (IMI, 4.8 micrograms/g; DMI, 1.8 micrograms/g) than in light (IMI, 2.85 micrograms/g; DMI, 0.85 microgram/g).",Chronopharmacokinetics of imipramine and desipramine in rat forebrain and plasma after single and chronic treatment with imipramine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1794155/),Î¼,1.8,222765,DB00458,Imipramine
,1794155,maximal brain concentrations (Cmax),"After single i.p. application of IMI, maximal brain concentrations (Cmax) of IMI and DMI were nearly twofold higher in darkness (IMI, 4.8 micrograms/g; DMI, 1.8 micrograms/g) than in light (IMI, 2.85 micrograms/g; DMI, 0.85 microgram/g).",Chronopharmacokinetics of imipramine and desipramine in rat forebrain and plasma after single and chronic treatment with imipramine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1794155/),[Î¼g] / [g],2.85,222766,DB00458,Imipramine
,1794155,maximal brain concentrations (Cmax),"After single i.p. application of IMI, maximal brain concentrations (Cmax) of IMI and DMI were nearly twofold higher in darkness (IMI, 4.8 micrograms/g; DMI, 1.8 micrograms/g) than in light (IMI, 2.85 micrograms/g; DMI, 0.85 microgram/g).",Chronopharmacokinetics of imipramine and desipramine in rat forebrain and plasma after single and chronic treatment with imipramine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1794155/),[Î¼g] / [g],0.85,222767,DB00458,Imipramine
,30564074,extraction recoveries,"Under the optimum experimental conditions, extraction recoveries and enrichment factors of the selected drugs ranged from 69-84 % and 345-420, respectively.",Determination of tricyclic antidepressants in human urine samples by the three-step sample pretreatment followed by HPLC-UV analysis: an efficient analytical method for further pharmacokinetic and forensic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30564074/),%,69-84,227547,DB00458,Imipramine
,30564074,enrichment factors,"Under the optimum experimental conditions, extraction recoveries and enrichment factors of the selected drugs ranged from 69-84 % and 345-420, respectively.",Determination of tricyclic antidepressants in human urine samples by the three-step sample pretreatment followed by HPLC-UV analysis: an efficient analytical method for further pharmacokinetic and forensic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30564074/),,345-420,227548,DB00458,Imipramine
,4010387,t1/2 TERM,Pharmacokinetic analyses by HPLC method with fluorescence detection demonstrated a dose-dependent rapid rise in plasma concentrations peaking in the 1st hr and declining rapidly thereafter (t1/2 TERM = 3 hrs).,"On acute and chronic CNS effects of antidepressants in normals: neurophysiological, behavioral and pharmacokinetic studies with pirlindol. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4010387/),h,3,229038,DB00458,Imipramine
,9839087,distribution volume,"At steady-state, acamprosate has a moderate distribution volume of about 20L.",Clinical pharmacokinetics of acamprosate. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9839087/),l,20,229746,DB00458,Imipramine
,9839087,terminal,The administration of the enteric-coated tablets showed a flip-flop mechanism with a terminal elimination half-life 10-fold higher than the 3-hour half-life reported after intravenous infusion.,Clinical pharmacokinetics of acamprosate. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9839087/),h,3,229747,DB00458,Imipramine
,9839087,accumulation ratio,"The pharmacokinetics of acamprosate administered as an enteric-coated tablets are time- and dose-independent, and its accumulation ratio is about 2.4 at steady-state.",Clinical pharmacokinetics of acamprosate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9839087/),,2.4,229748,DB00458,Imipramine
,11292004,steady-state total serum concentrations,After 2 weeks of combination therapy a significant decrease in mean steady-state total serum concentrations of IMI (from 168.84 +/- 102.18 to 98.12 +/- 43.79 ng/ml) and DMI (from 293.89 +/- 171.93 to 221.85 +/- 153.21 ng/ml) was observed.,Pharmacokinetic interaction between imipramine and carbamazepine in patients with major depression. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11292004/),[ng] / [ml],168.84,232536,DB00458,Imipramine
,11292004,steady-state total serum concentrations,After 2 weeks of combination therapy a significant decrease in mean steady-state total serum concentrations of IMI (from 168.84 +/- 102.18 to 98.12 +/- 43.79 ng/ml) and DMI (from 293.89 +/- 171.93 to 221.85 +/- 153.21 ng/ml) was observed.,Pharmacokinetic interaction between imipramine and carbamazepine in patients with major depression. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11292004/),[ng] / [ml],98.12,232537,DB00458,Imipramine
,11292004,steady-state total serum concentrations,After 2 weeks of combination therapy a significant decrease in mean steady-state total serum concentrations of IMI (from 168.84 +/- 102.18 to 98.12 +/- 43.79 ng/ml) and DMI (from 293.89 +/- 171.93 to 221.85 +/- 153.21 ng/ml) was observed.,Pharmacokinetic interaction between imipramine and carbamazepine in patients with major depression. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11292004/),[ng] / [ml],293.89,232538,DB00458,Imipramine
,11292004,steady-state total serum concentrations,After 2 weeks of combination therapy a significant decrease in mean steady-state total serum concentrations of IMI (from 168.84 +/- 102.18 to 98.12 +/- 43.79 ng/ml) and DMI (from 293.89 +/- 171.93 to 221.85 +/- 153.21 ng/ml) was observed.,Pharmacokinetic interaction between imipramine and carbamazepine in patients with major depression. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11292004/),[ng] / [ml],221.85,232539,DB00458,Imipramine
,412206,half-lives,The half-lives of clomipramine after oral administration ranged from 11.6-35.8 h (M = 20.8 +/- 4.0) and after intramuscular administration from 20.1--39.6 h (M = 24.7 +/- 3.7).,The demethylation of imipramine and clomipramine as apparent from their plasma kinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/412206/),h,11.6-35.8,239135,DB00458,Imipramine
,412206,half-lives,The half-lives of clomipramine after oral administration ranged from 11.6-35.8 h (M = 20.8 +/- 4.0) and after intramuscular administration from 20.1--39.6 h (M = 24.7 +/- 3.7).,The demethylation of imipramine and clomipramine as apparent from their plasma kinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/412206/),h,20.8,239136,DB00458,Imipramine
,412206,half-lives,The half-lives of clomipramine after oral administration ranged from 11.6-35.8 h (M = 20.8 +/- 4.0) and after intramuscular administration from 20.1--39.6 h (M = 24.7 +/- 3.7).,The demethylation of imipramine and clomipramine as apparent from their plasma kinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/412206/),h,20.1--39.6,239137,DB00458,Imipramine
,412206,half-lives,The half-lives of clomipramine after oral administration ranged from 11.6-35.8 h (M = 20.8 +/- 4.0) and after intramuscular administration from 20.1--39.6 h (M = 24.7 +/- 3.7).,The demethylation of imipramine and clomipramine as apparent from their plasma kinetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/412206/),,24.7,239138,DB00458,Imipramine
,24071566,t(max),"LY2456302 exhibits canonical pharmacokinetic properties that are favorable for clinical development, with rapid absorption (t(max): 1-2 h) and good oral bioavailability (F = 25%).","LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24071566/),h,1-2,241686,DB00458,Imipramine
,24071566,oral bioavailability (F,"LY2456302 exhibits canonical pharmacokinetic properties that are favorable for clinical development, with rapid absorption (t(max): 1-2 h) and good oral bioavailability (F = 25%).","LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24071566/),%,25,241687,DB00458,Imipramine
,24071566,EDââ,"Oral LY2456302 administration selectively and potently occupied central kappa opioid receptors in vivo (EDââ = 0.33 mg/kg), without evidence of mu or delta receptor occupancy at doses up to 30 mg/kg.","LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24071566/),[mg] / [kg],0.33,241688,DB00458,Imipramine
,3965690,half-life,"Imipramine half-life was markedly prolonged in elderly vs. young males (28.6 vs. 16.5 hr; P less than .001) and females (30.2 vs. 17.8 hr; P less than .01) due to decreased clearance (males: 567 vs. 945 ml/min, P less than .01; females: 599 vs. 975 ml/min, P less than .005) with no change in volume of distribution.",Imipramine and desipramine disposition in the elderly. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3965690/),h,28.6,243635,DB00458,Imipramine
,3965690,half-life,"Imipramine half-life was markedly prolonged in elderly vs. young males (28.6 vs. 16.5 hr; P less than .001) and females (30.2 vs. 17.8 hr; P less than .01) due to decreased clearance (males: 567 vs. 945 ml/min, P less than .01; females: 599 vs. 975 ml/min, P less than .005) with no change in volume of distribution.",Imipramine and desipramine disposition in the elderly. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3965690/),h,16.5,243636,DB00458,Imipramine
,3965690,half-life,"Imipramine half-life was markedly prolonged in elderly vs. young males (28.6 vs. 16.5 hr; P less than .001) and females (30.2 vs. 17.8 hr; P less than .01) due to decreased clearance (males: 567 vs. 945 ml/min, P less than .01; females: 599 vs. 975 ml/min, P less than .005) with no change in volume of distribution.",Imipramine and desipramine disposition in the elderly. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3965690/),h,30.2,243637,DB00458,Imipramine
,3965690,half-life,"Imipramine half-life was markedly prolonged in elderly vs. young males (28.6 vs. 16.5 hr; P less than .001) and females (30.2 vs. 17.8 hr; P less than .01) due to decreased clearance (males: 567 vs. 945 ml/min, P less than .01; females: 599 vs. 975 ml/min, P less than .005) with no change in volume of distribution.",Imipramine and desipramine disposition in the elderly. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3965690/),h,17.8,243638,DB00458,Imipramine
,3965690,clearance,"Imipramine half-life was markedly prolonged in elderly vs. young males (28.6 vs. 16.5 hr; P less than .001) and females (30.2 vs. 17.8 hr; P less than .01) due to decreased clearance (males: 567 vs. 945 ml/min, P less than .01; females: 599 vs. 975 ml/min, P less than .005) with no change in volume of distribution.",Imipramine and desipramine disposition in the elderly. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3965690/),[ml] / [min],567,243639,DB00458,Imipramine
,3965690,clearance,"Imipramine half-life was markedly prolonged in elderly vs. young males (28.6 vs. 16.5 hr; P less than .001) and females (30.2 vs. 17.8 hr; P less than .01) due to decreased clearance (males: 567 vs. 945 ml/min, P less than .01; females: 599 vs. 975 ml/min, P less than .005) with no change in volume of distribution.",Imipramine and desipramine disposition in the elderly. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3965690/),[ml] / [min],945,243640,DB00458,Imipramine
,3965690,clearance,"Imipramine half-life was markedly prolonged in elderly vs. young males (28.6 vs. 16.5 hr; P less than .001) and females (30.2 vs. 17.8 hr; P less than .01) due to decreased clearance (males: 567 vs. 945 ml/min, P less than .01; females: 599 vs. 975 ml/min, P less than .005) with no change in volume of distribution.",Imipramine and desipramine disposition in the elderly. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3965690/),[ml] / [min],599,243641,DB00458,Imipramine
,3965690,clearance,"Imipramine half-life was markedly prolonged in elderly vs. young males (28.6 vs. 16.5 hr; P less than .001) and females (30.2 vs. 17.8 hr; P less than .01) due to decreased clearance (males: 567 vs. 945 ml/min, P less than .01; females: 599 vs. 975 ml/min, P less than .005) with no change in volume of distribution.",Imipramine and desipramine disposition in the elderly. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3965690/),[ml] / [min],975,243642,DB00458,Imipramine
,3965690,time to peak imipramine concentration,After p.o. imipramine doses time to peak imipramine concentration was shorter in elderly females (2.1 vs. 4.8 hr; P less than .005) but no different in males.,Imipramine and desipramine disposition in the elderly. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3965690/),h,2.1,243643,DB00458,Imipramine
,3965690,time to peak imipramine concentration,After p.o. imipramine doses time to peak imipramine concentration was shorter in elderly females (2.1 vs. 4.8 hr; P less than .005) but no different in males.,Imipramine and desipramine disposition in the elderly. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3965690/),h,4.8,243644,DB00458,Imipramine
,3965690,Peak concentration achieved,"Peak concentration achieved was greater in the elderly of both sexes (males: 40.2 vs. 19.5 ng/ml, P less than .005; females: 44.7 vs. 10.4 ng/ml, P less than .01).",Imipramine and desipramine disposition in the elderly. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3965690/),[ng] / [ml],40.2,243645,DB00458,Imipramine
,3965690,Peak concentration achieved,"Peak concentration achieved was greater in the elderly of both sexes (males: 40.2 vs. 19.5 ng/ml, P less than .005; females: 44.7 vs. 10.4 ng/ml, P less than .01).",Imipramine and desipramine disposition in the elderly. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3965690/),[ng] / [ml],19.5,243646,DB00458,Imipramine
,3965690,Peak concentration achieved,"Peak concentration achieved was greater in the elderly of both sexes (males: 40.2 vs. 19.5 ng/ml, P less than .005; females: 44.7 vs. 10.4 ng/ml, P less than .01).",Imipramine and desipramine disposition in the elderly. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3965690/),[ng] / [ml],44.7,243647,DB00458,Imipramine
,3965690,Peak concentration achieved,"Peak concentration achieved was greater in the elderly of both sexes (males: 40.2 vs. 19.5 ng/ml, P less than .005; females: 44.7 vs. 10.4 ng/ml, P less than .01).",Imipramine and desipramine disposition in the elderly. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3965690/),[ng] / [ml],10.4,243648,DB00458,Imipramine
,3965690,half-life,Desipramine half-life was slightly prolonged in elderly males (30.8 vs. 21.2 hr; P less than .05) apparently related to a nonsignificant decrease in p.o. clearance.,Imipramine and desipramine disposition in the elderly. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3965690/),h,30.8,243649,DB00458,Imipramine
,3965690,half-life,Desipramine half-life was slightly prolonged in elderly males (30.8 vs. 21.2 hr; P less than .05) apparently related to a nonsignificant decrease in p.o. clearance.,Imipramine and desipramine disposition in the elderly. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3965690/),h,21.2,243650,DB00458,Imipramine
,23420715,m,The ion transitions monitored in positive-ion mode [M + H](+) of multiple-reaction monitoring were m/z 397.0 â 260.2 for PF-04620110 and m/z 280.8 â 86.0 for imipramine.,"Determination of PF-04620110, a novel inhibitor of diacylglycerol acyltransferase-1, in rat plasma using liquid chromatography-tandem mass spectrometry and its application in pharmacokinetic studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23420715/),,397.0,245472,DB00458,Imipramine
,23420715,m/z,The ion transitions monitored in positive-ion mode [M + H](+) of multiple-reaction monitoring were m/z 397.0 â 260.2 for PF-04620110 and m/z 280.8 â 86.0 for imipramine.,"Determination of PF-04620110, a novel inhibitor of diacylglycerol acyltransferase-1, in rat plasma using liquid chromatography-tandem mass spectrometry and its application in pharmacokinetic studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23420715/),,280.8,245473,DB00458,Imipramine
,23420715,m/z,The ion transitions monitored in positive-ion mode [M + H](+) of multiple-reaction monitoring were m/z 397.0 â 260.2 for PF-04620110 and m/z 280.8 â 86.0 for imipramine.,"Determination of PF-04620110, a novel inhibitor of diacylglycerol acyltransferase-1, in rat plasma using liquid chromatography-tandem mass spectrometry and its application in pharmacokinetic studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23420715/),,86.0,245474,DB00458,Imipramine
â¥,23420715,signal-to-noise ratios,The detector response was specific and linear for PF-04620110 at concentrations within the range 0.05-50 Âµg/mL and the signal-to-noise ratios for the samples were â¥10.,"Determination of PF-04620110, a novel inhibitor of diacylglycerol acyltransferase-1, in rat plasma using liquid chromatography-tandem mass spectrometry and its application in pharmacokinetic studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23420715/),,10,245475,DB00458,Imipramine
,18254143,total chromatographic run time,"The total chromatographic run time was 3.0 min and the elution of DFL and IS occurred at approximately 1.46 and 2.15 min, respectively.",Development and validation of a sensitive LC-MS/MS method with electrospray ionization for quantitation of doxofylline in human serum: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18254143/),min,3.0,251739,DB00458,Imipramine
,18254143,ion transitions,The MS/MS ion transitions monitored were 267.5 --> 181.1 for DFL and 281.1 --> 86.2 for IS.,Development and validation of a sensitive LC-MS/MS method with electrospray ionization for quantitation of doxofylline in human serum: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18254143/),,267.5,251740,DB00458,Imipramine
,18254143,ion transitions,The MS/MS ion transitions monitored were 267.5 --> 181.1 for DFL and 281.1 --> 86.2 for IS.,Development and validation of a sensitive LC-MS/MS method with electrospray ionization for quantitation of doxofylline in human serum: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18254143/),,181.1,251741,DB00458,Imipramine
,18254143,ion transitions,The MS/MS ion transitions monitored were 267.5 --> 181.1 for DFL and 281.1 --> 86.2 for IS.,Development and validation of a sensitive LC-MS/MS method with electrospray ionization for quantitation of doxofylline in human serum: application to a clinical pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18254143/),,281.1,251742,DB00458,Imipramine
,9572296,Ka,"One was a murine monoclonal IgG1 (Ka = 3.8 x 10(7) M(-1)) at an IgG/IMI molar ratio of 1,000 (IgG1,000), and the other was a sheep polyclonal IgG (TAb; Ka = 1.3 x 10(10) M(-1)) at IgG/IMI molar ratios of 1, 10, and 100 (TAb1, TAb10, and TAb100).",Redistribution of imipramine from regions of the brain under the influence of circulating specific antibodies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9572296/),1/[M],3.8 x 10(7),252008,DB00458,Imipramine
,9572296,Ka,"One was a murine monoclonal IgG1 (Ka = 3.8 x 10(7) M(-1)) at an IgG/IMI molar ratio of 1,000 (IgG1,000), and the other was a sheep polyclonal IgG (TAb; Ka = 1.3 x 10(10) M(-1)) at IgG/IMI molar ratios of 1, 10, and 100 (TAb1, TAb10, and TAb100).",Redistribution of imipramine from regions of the brain under the influence of circulating specific antibodies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9572296/),1/[M],1.3 x 10(10),252009,DB00458,Imipramine
,9572296,Cmax,"In the control rats, IMI was rapidly taken up by the brain (Cmax at 5 min) with no significant differences among the brain regions (4.1 +/- 0.4 to 5.4 +/- 0.6 pmol/ g), and brain IMI then declined monoexponentially with a half-life of 44.2 min (cerebellum) to 77.3 min (hippocampus).",Redistribution of imipramine from regions of the brain under the influence of circulating specific antibodies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9572296/),,4,252010,DB00458,Imipramine
,9572296,half-life,"In the control rats, IMI was rapidly taken up by the brain (Cmax at 5 min) with no significant differences among the brain regions (4.1 +/- 0.4 to 5.4 +/- 0.6 pmol/ g), and brain IMI then declined monoexponentially with a half-life of 44.2 min (cerebellum) to 77.3 min (hippocampus).",Redistribution of imipramine from regions of the brain under the influence of circulating specific antibodies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9572296/),min,44.2,252011,DB00458,Imipramine
,9572296,half-life,"In the control rats, IMI was rapidly taken up by the brain (Cmax at 5 min) with no significant differences among the brain regions (4.1 +/- 0.4 to 5.4 +/- 0.6 pmol/ g), and brain IMI then declined monoexponentially with a half-life of 44.2 min (cerebellum) to 77.3 min (hippocampus).",Redistribution of imipramine from regions of the brain under the influence of circulating specific antibodies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9572296/),min,77.3,252012,DB00458,Imipramine
,9572296,fraction,"The fraction of IMI removed from the brain was 58-74%, and the redistribution half-life was 7.9-15.6 min; the mean residence time was reduced by 66-75% (11.8-23.9 min).",Redistribution of imipramine from regions of the brain under the influence of circulating specific antibodies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9572296/),%,58-74,252013,DB00458,Imipramine
,9572296,redistribution half-life,"The fraction of IMI removed from the brain was 58-74%, and the redistribution half-life was 7.9-15.6 min; the mean residence time was reduced by 66-75% (11.8-23.9 min).",Redistribution of imipramine from regions of the brain under the influence of circulating specific antibodies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9572296/),min,7.9-15.6,252014,DB00458,Imipramine
,1120401,half-lives of the terminal phase,Estimated half-lives of the terminal phase ranged from 7 to 11 hr.,Pharmacokinetics of bethanidine in hypertensive patients. ,"t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1120401/),h,7 to 11,254406,DB00458,Imipramine
,1281075,elimination half-life,Its elimination half-life (approximately 26 hours) makes it suitable for once daily administration.,"Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive-compulsive disorder. ","t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1281075/),h,26,267086,DB00458,Imipramine
,6475108,total excretion,The total excretion of 14C-labelled metabolites in urine of galactosamine-treated rats was 69% dose compared with 37% in untreated animals.,The metabolism and excretion of [14C]imipramine in an experimental hepatitis. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6475108/),%,69,270482,DB00458,Imipramine
,6475108,total excretion,The total excretion of 14C-labelled metabolites in urine of galactosamine-treated rats was 69% dose compared with 37% in untreated animals.,The metabolism and excretion of [14C]imipramine in an experimental hepatitis. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6475108/),%,37,270483,DB00458,Imipramine
,6475108,Faecal excretion,Faecal excretion of [14C]imipramine metabolites was lowered from 68% dose in untreated animals to 27% in animals with induced hepatitis.,The metabolism and excretion of [14C]imipramine in an experimental hepatitis. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6475108/),%,68,270484,DB00458,Imipramine
,6475108,Faecal excretion,Faecal excretion of [14C]imipramine metabolites was lowered from 68% dose in untreated animals to 27% in animals with induced hepatitis.,The metabolism and excretion of [14C]imipramine in an experimental hepatitis. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6475108/),%,27,270485,DB00458,Imipramine
,23494651,m/,"The ions utilized for quantification of azithromycin and IS were m/z 749.6 (M + H)(+) and m/z 591.4 (fragment) for azithromycin, and 281.1 m/z for internal standard; retention times were 6.9 and 3.4 min, respectively.",A liquid chromatography-mass spectrometric method for the quantification of azithromycin in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23494651/),,749.6,272216,DB00458,Imipramine
,23494651,retention times,"The ions utilized for quantification of azithromycin and IS were m/z 749.6 (M + H)(+) and m/z 591.4 (fragment) for azithromycin, and 281.1 m/z for internal standard; retention times were 6.9 and 3.4 min, respectively.",A liquid chromatography-mass spectrometric method for the quantification of azithromycin in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23494651/),min,6.9,272217,DB00458,Imipramine
,23494651,retention times,"The ions utilized for quantification of azithromycin and IS were m/z 749.6 (M + H)(+) and m/z 591.4 (fragment) for azithromycin, and 281.1 m/z for internal standard; retention times were 6.9 and 3.4 min, respectively.",A liquid chromatography-mass spectrometric method for the quantification of azithromycin in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23494651/),min,3.4,272218,DB00458,Imipramine
>,23494651,absolute recoveries,The mean absolute recoveries for 50 and 500 ng/mL azithromycin and 1 Âµg/ mL IS were >75%.,A liquid chromatography-mass spectrometric method for the quantification of azithromycin in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23494651/),%,75,272219,DB00458,Imipramine
